<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.09.07.21263194</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficac</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8811-195X</contrib-id>
<name><surname>Focosi</surname><given-names>Daniele</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8414-6389</contrib-id>
<name><surname>Franchini</surname><given-names>Massimo</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7568-2961</contrib-id>
<name><surname>Pirofski</surname><given-names>Liise-anne</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0507-9243</contrib-id>
<name><surname>Burnouf</surname><given-names>Thierry</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0151-966X</contrib-id>
<name><surname>Paneth</surname><given-names>Nigel</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7135-7643</contrib-id>
<name><surname>Joyner</surname><given-names>Michael J.</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9402-9167</contrib-id>
<name><surname>Casadevall</surname><given-names>Arturo</given-names></name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<aff id="a1"><label>1</label><institution>North-Western Tuscany Blood Bank, Pisa University Hospital</institution>, Pisa, <country>Italy</country>.</aff>
<aff id="a2"><label>2</label><institution>Division of Transfusion Medicine, Carlo Poma Hospital</institution>, 46100 Mantua, <country>Italy</country>; <email>massimo.franchini@asst-mantova.it</email></aff>
<aff id="a3"><label>3</label><institution>Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center</institution>, New York, NY 10467, <country>USA</country>; <email>l.pirofski@einsteinmed.org</email></aff>
<aff id="a4"><label>4</label><institution>Graduate Institute of Biomedical Materials and Tissue Engineering &#x0026; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</institution>, <country>Taiwan</country>; <email>thburnouf@gmail.com</email></aff>
<aff id="a5"><label>5</label><institution>Departments of Epidemiology &#x0026; Biostatistics and Pediatrics &#x0026; Human Development, College of Human Medicine, Michigan State University</institution>, East Lansing, MI 48824, <email>paneth@msu.edu</email></aff>
<aff id="a6"><label>6</label><institution>Department of Anesthesiology and Perioperative Medicine</institution>, Mayo Clinic, Rochester, MN, <country>USA</country>; <email>joyner.michael@mayo.edu</email></aff>
<aff id="a7"><label>7</label><institution>Department of Medicine, Johns Hopkins School of Public Health and School of Medicine</institution>, Baltimore, MD, USA; <email>acasade1@jhu.edu</email></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x0023;</label>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: <email>daniele.focosi@gmail.com</email></corresp>
<fn id="n1" fn-type="abbr"><p><bold>Abbreviations</bold>: BSC : best supportive care; CP : convalescent plasma; CCP : COVID-19 convalescent plasma; nAbs : neutralizing antibodies; VNT: viral neutralization test;</p></fn>
<fn id="n2" fn-type="con"><p><bold>Author contributions</bold>: D.F. designed the paper, analyzed the data, and wrote the first draft. M.F., M.J.J., T.B., L.P., N.P. and A.C. revised the manuscript. All authors approved the final version.</p></fn>
</author-notes>
<pub-date pub-type="epub"><year>2021</year></pub-date>
<elocation-id>2021.09.07.21263194</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>9</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>9</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>9</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21263194.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title><p>Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light into mechanisms of action, safety and efficacy of convalescent plasma using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCT) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in more doubt than certainty. Reasons for CCP success and failure may be hidden in study details, which are usually difficult to explain to physicians and the public but provide fertile ground for designing next-generation studies. In this paper we analyzed variables associated with efficacy such as clinical settings, disease severity, CCP SARS-CoV-2 antibody levels and function, dose, timing of administration (variously defined as time from onset of symptoms, molecular diagnosis, diagnosis of pneumonia, or hospitalization, or by serostatus), outcomes (defined as hospitalization, requirement for ventilation, clinical improvement or mortality), CCP provenance and time for collection, and criteria for efficacy. Focusing only on the results from the 23 available RCT we noted that these were more likely to show signals of efficacy, including reductions in mortality, if the plasma neutralizing titer was &#x2265; 160 and the time to randomization was &#x2264; 9 days, consistent with passive antibody therapy efficacy requiring dosing with sufficient antibody. The fact that most studies revealed signals of efficacy despite variability in CCP and its use suggest robust therapeutic effects that become apparent despite the data noise.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>COVID-19</kwd>
<kwd>convalescent plasma</kwd>
<kwd>randomized clinical trial</kwd>
<kwd>propensity score-matched</kwd>
<kwd>neutralizing antibodies</kwd>
<kwd>viral neutralization tests.</kwd>
</kwd-group>
<counts>
<page-count count="45"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No external funding was received.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Not applicable</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p> I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>In the first 21 years of the 21<sup>st</sup> century humanity has experienced six major epidemics. The agents involved were SARS-CoV, MERS, influenza A(H<sub>1</sub>N<sub>1</sub>), Ebola, Zika and SARS-CoV-2 viruses. For five of these outbreaks the response included the use of convalescent plasma (CP) (reviewed in (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>)) and it was considered for the sixth (Zika virus). The attraction of CP is that it is readily available as soon as there are convalescing survivors, that unlike drugs or monoclonal antibodies it needs no development, and it is polyclonal, cheap and deployable even in resource poor countries. CP has been proposed as a first line response to new pandemics (<xref ref-type="bibr" rid="c3">3</xref>) and was deployed during the COVID-19 pandemic in March 2020 in countries that experienced the early waves of disease such as China (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref>) and Italy (<xref ref-type="bibr" rid="c6">6</xref>).</p>
<p>While in early 2020 most clinical use was reported in case series or small phase II clinical trials (<xref ref-type="bibr" rid="c7">7</xref>), beginning in late March 2020 the US expanded access program (EAP) generated a large and robust treatment dataset, with insights on safety and optimal use. This database provided the first clear evidence that CP is safe, which was important given that early in the pandemic there were significant concerns about antibody-dependent enhancement (<xref ref-type="bibr" rid="c8">8</xref>). Later, an analysis of the first 3082 patents within the EAP database provided evidence that associated early administration of high titer CCP to non-ventilated hospitalized patients with reduced mortality (<xref ref-type="bibr" rid="c9">9</xref>). Before the FDA granted emergency use authorization (EUA), the US EAP provided CCP to as many as 94,287 patients. During the past year, many studies employing either randomized controls (RCT) or propensity score-matched (PSM) controls have been published. RCTs and PSM studies reported so far have had largely opposite outcomes, with most but not all RCTs finding little overall effect on mortality while the PSM and many smaller trials reporting mortality benefits. Several RCTs did not have mortality as a primary endpoint or it was part of a composite endpoint (<xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c10">10</xref>&#x2013;<xref ref-type="bibr" rid="c12">12</xref>). These disparate results have led to confusion for both the public and the clinicians, leading to reduced enthusiasm for the use of CP, in part because RCT data is more influential in affecting the opinion of many physicians, specialty societies and government regulators.</p>
<p>As with any other medical treatment, several key factors should be taken into account when evaluating a trial, including the indication (which can be estimated by timing or clinical severity), the therapeutic dose and the intended outcomes. The choices made by the trial designers determine whether the trial will demonstrate or conceal clinical benefit. While much attention is appropriately focused on the performance features of clinical trials (sample size, fidelity to randomization, appropriate analysis), the biological rationale for the hypothesis being tested is critically important but not always taken into account.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>On September 7, 2021, we searched PubMed (which is also indexing the medrXiv prepublishing server) for clinical trials of CCP in COVID19, focusing on RCTs and PSM studies only. Each study was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of efficacy, and reasons for failure At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as status &#x201C;completed&#x201D;, &#x201C;active, not yet recruiting&#x201D; or &#x201C;recruiting&#x201D;.</p>
</sec>
<sec id="s3">
<title>Results</title>
<p>PubMed search retrieved 23 RCTs and 12 PSM studies about CCP, whose main variables are summarized in <xref rid="tbl2" ref-type="table">Tables 2</xref> and <xref rid="tbl3" ref-type="table">3</xref>. The characteristics of the VNTs used are summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>. The variables were reconciled in 4 major topics, discussed in the following sections: the indication, the therapeutic doses, the relevance of CCP to the viral variant, and the intended outcome.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1</label>
<caption><p>Details of viral neutralization tests (VNT) employed in CCP RCTs. Information was retrieved from original article (including Supplementary Appendix). Whenever not reported, the corresponding author was contacted (marked with &#x002A;). If the details could not be retrieved the field is labelled &#x201C;n.a.&#x201D; (not available). IC: inhibitory concentration. NT: neutralization titer. PFU: plaque-forming unit.</p></caption>
<graphic xlink:href="21263194v1_tbl1a.tif"/>
<graphic xlink:href="21263194v1_tbl1b.tif"/>
<graphic xlink:href="21263194v1_tbl1c.tif"/>
<graphic xlink:href="21263194v1_tbl1d.tif"/>
</table-wrap>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2</label>
<caption><p>Randomized controlled trials (RCT) of COVID-19 convalescent plasma (CCP) reported to date. nAb: neutralizing antibodies. BSC: best supportive care. FFP: fresh frozen (nonconvalescent) plasma. n.a.: not assessed (i.e. antivirus antibodies were assessed only using high-throughput serology). IQR: interquartile range.</p></caption>
<graphic xlink:href="21263194v1_tbl2a.tif"/>
<graphic xlink:href="21263194v1_tbl2b.tif"/>
<graphic xlink:href="21263194v1_tbl2c.tif"/>
<graphic xlink:href="21263194v1_tbl2d.tif"/>
<graphic xlink:href="21263194v1_tbl2e.tif"/>
<graphic xlink:href="21263194v1_tbl2f.tif"/>
<graphic xlink:href="21263194v1_tbl2g.tif"/>
</table-wrap>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3</label>
<caption><p>Propensity score-matched (PSM) CCP studies reported to date. DPH: days post-hospitalization. None of these studies titered nAbs in either donor or recipient using NT.</p></caption>
<graphic xlink:href="21263194v1_tbl3a.tif"/>
<graphic xlink:href="21263194v1_tbl3b.tif"/>
<graphic xlink:href="21263194v1_tbl3c.tif"/>
</table-wrap>
<p>ClinicalTrials.gov search retrieved 8 CCP RCTs completed but not yet prepublished or published, 7 active but not yet recruiting RCTs, and 10 RCTs which are still recruiting (summarized in <xref rid="tbl4" ref-type="table">Table 4</xref>).</p>
<table-wrap id="tbl4" orientation="portrait" position="float">
<label>Table 4</label>
<caption><p>Summary of completed but not yet reported or ongoing RCTs of CCP, as registered on ClinicalTrials.gov as of August 26, 2021. BSC: best supportive care; FFP: fresh frozen plasma. Several studies were withdrawn (NCT04377568).</p></caption>
<graphic xlink:href="21263194v1_tbl4a.tif"/>
<graphic xlink:href="21263194v1_tbl4b.tif"/>
<graphic xlink:href="21263194v1_tbl4c.tif"/>
</table-wrap>
<sec id="s3a">
<title>The indication</title>
<p>While it would be desirable to have a single drug that works at any disease stage, it was not reasonable to expect a silver bullet effect from neutralizing antibody-based treatments such as CCP in later stages of disease. COVID-19 is now well-defined as a disease with two stages, an initial viral phase characterized by flu-like and upper and lower respiratory symptoms, followed, in severe cases, by an inflammatory phase that is characterized by inflammation-driven damage to multiple organ systems, including the lungs that can impair gas exchange and cause life-threatening hypoxia and damage to multiple organs, including the brain and blood vessels (<xref ref-type="bibr" rid="c13">13</xref>). Specific intact antibodies in CCP are expected to neutralize SARS-CoV-2 in the intravascular system and, in some patients, prevent progression from early to severe and life-threatening disease (as seen in animal models (<xref ref-type="bibr" rid="c14">14</xref>)), but this antiviral therapy cannot be expected to reverse the inflammatory phase of the disease, nor neutralize infectious viruses invading the extravascular system. Thus, COVID-19 is similar to influenza, a disease in which antivirals are effective early in disease but have no effect in later stages when the symptomatology stems largely from the inflammatory response. The rationale for administering CCP as early as possible in the course of COVID-19 stems from the neutralization stoichiometry itself: the larger the number of actively replicating virions in the body, the higher the nAb dose needed for neutralization (<xref ref-type="bibr" rid="c15">15</xref>). Some uncontrolled studies have reported a lack of association between early intervention and outcomes (<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>), but in these studies the level of neutralizing antibody (nAb) or the overall anti-Spike antibody level in the infused CCP was unknown, leaving room for alternative explanations.</p>
<p>At the beginning of the pandemic, some investigators and opinion leaders, riding the wave of CCP successes in anecdotal reports in the media and small case series, introduced CCP to the general public as a panacea for any patient with COVID-19, including life-threatening cases, leading to confusing messaging: after reports of failure in severely ill patients emerged, opinions became polarized and the debate became everything but scientific (<xref ref-type="bibr" rid="c18">18</xref>). In clinical trials, the indication (i.e., the baseline clinical setting) has been variously defined by patient status (outpatient vs. presenting to the emergency room vs. hospitalized vs. ICU-admitted), disease severity (using 5-category COVID-19 Outpatient Ordinal Outcome Scale (<xref ref-type="bibr" rid="c19">19</xref>), a 6-category ordinal scale (<xref ref-type="bibr" rid="c12">12</xref>), a 7-category COVID-19 severity scale (<xref ref-type="bibr" rid="c20">20</xref>), the WHO 8- (<xref ref-type="bibr" rid="c21">21</xref>) or 11-category (<xref ref-type="bibr" rid="c22">22</xref>) ordinal scales, or pneumological scores such as SOFA), the time elapsed before recruitment (also variably defined as from molecular diagnosis, from onset of hospitalization, from diagnosis of pneumonia, or from onset of symptoms), or by serological status (presence of antibodies or the ability to neutralize SARS-CoV-2). This variability in inclusion criteria for studies has resulted in marked heterogeneity in recruited patients.</p>
<p>An additional complexity in recruitment to CCP trials is time to treatment. Clinical trials involve administrative requirements and consent procedures, and recruitment to a RCT further requires randomization, which may produce delays in treatment. CCP therapy requires matching on blood type, ordering the CCP, which may or may not be available on site, and setting up the transfusion. This inherent delay from randomization to infusion means that RCTs may build in a disadvantage for the CCP study arm, where controls may have received treatment earlier in the disease course (as, for example, in the CP3O trial (<xref ref-type="bibr" rid="c23">23</xref>). ABO-compatible CCP units may be not readily available at the local blood bank and recruited patients may have to wait for a compatible unit of CCP. These almost inevitable delays from randomization mean that CCP may be provided later in the illness than is ideal, and even if the trial intends to treat early, in practice it may not be possible.</p>
<p>During a pandemic, moreover, delays in treatment are magnified. The accrual of severely ill patients in emergency departments and the overwhelmed or even collapsed health care systems can create long delays from arrival in the emergency room to treatment. In the absence of quick (antigenic or molecular) tests for SARS-CoV-2, the turnaround time for final confirmation of diagnosis with PCR, which must often be run in batches, can take several hours. All of these factors are likely to impact the efficacy of CCP treatment. To shorten such time, fully screened CCP collected from eligible donors (<xref ref-type="bibr" rid="c24">24</xref>) could be safely administered within emergency departments shortly after admission and even before the patient reaches the ward.</p>
</sec>
<sec id="s3b">
<title>The therapeutic dose</title>
<p>Determining the effective dose of CCP is difficult in a pandemic because the antibody assays and other tests needed to assess the potency of any antibody product take time to be developed. In practice, the effective dose is the product of multiple factors, none of which is fully standardized. The first factor is the concentration of the nAbs as measured by a VNT. At the beginning of the pandemic, only a few BSL3 (or higher)-equipped virology laboratories could run VNT using authentic live SARS- CoV-2 virus: the procedure was time-consuming (3-5 days) and the reports were operator-dependent. Nowadays, the availability of Spike-pseudotyped viruses which can be managed under the more widely available BSL-2 laboratories, or cell-free ACE-2 competition assays, combined with automated (e.g., luminescence-based) readings, have standardized outcomes and shortened turnaround times (<xref ref-type="bibr" rid="c25">25</xref>): however, harmonization between different assays is still a work in progress (<xref ref-type="bibr" rid="c26">26</xref>). The VNT differs according to the type of replication-competent cell line, the viral isolate used for the challenge (which is critically important when the virus is mutating rapidly as has been the case with emergence of variants of concern), the multiplicity of infection (i.e., the ratio between the viral inoculum - referred with different measuring units &#x2013; and the number of replication-competent cells within each well), the detection system (optic microscopy for cytopathic effect, immunostaining, quantitative PCR, or luminometer for engineered pseudoviruses), and finally the threshold of neutralization (50&#x0025; or 90&#x0025;). The DAWN-plasma RCT provides a clear example of such heterogeneity, with 4 different VNTs used in at different participating laboratories. It was not until August 2020, when many trials were already underway, that the FDA Emergency Use Authorization 26382 defined high-titer CCP on the basis of correlation with a reference standard, the Broad Institute the live-virus, 5-dilution VNT as a 50&#x0025; inhibitory dilution (ID<sub>50</sub>) of 1:250 or more (<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/141481/download">https://www.fda.gov/media/141481/download</ext-link> ), and exclusive use of high-titer CCP was formally recommended by the FDA only on March 9, 2021.</p>
<p><xref rid="tbl1" ref-type="table">Table 1</xref> summarizes the key variables in VNT employed to date in CCP RCTs. Published trials have varied greatly in their approaches to antibody quantification whether in measured transfused CCP units or in recipients. Many trials have relied on high-throughput semi-quantitative or qualitative assays with a poor-to-moderate relationship with nAb titers. Although most trials performed a correlation analysis between VNT and high-throughput serological assays, in many cases the CCP units were tested only with the latter without validation, as was the case with 66&#x0025; of the patients in the PlasmAR trial (<xref ref-type="bibr" rid="c12">12</xref>). This procedure risks an incorrect evaluation of the neutralizing CCP activity. Another cause for discrepancies in outcomes could be that although IgM, IgG, and IgA are all capable of mediating neutralization, VNT titers correlate better with binding levels of IgM and IgA<sub>1</sub> than they do with IgG (<xref ref-type="bibr" rid="c27">27</xref>). Yet it is IgG that is routinely measured in high-throughput serological assays, and these assays include non-neutralizing IgGs, the role of which in activity against SARS- CoV-2 has not been established. Trials should preferentially use VNTs to assess serostatus of transfused units and not rely on high-throughput serology.</p>
<p>As for any other medicinal product, CCP exhibits a dose-response relationship, which is also evident when using high-throughput assays. In the subgroup analysis of the EAP, a gradient of mortality was seen in relation to IgG antibody levels in the transfused CCP. In the subgroup of patients who were not receiving mechanical ventilation, death within 30 days after CCP transfusion occurred in 81 of 365 patients (22.2&#x0025;; 95&#x0025; CI, 18.2 to 26.7) in the low titer group, 251 of 1297 patients (19.4&#x0025;; 95&#x0025; CI, to 21.6) in the medium-titer group, and 50 of 352 patients (14.2&#x0025;; 95&#x0025; CI, 10.9 to 18.2) in the high-titer group. Depending on the statistical model, the RR for 30-day mortality in high-titer CCP compared to low-titer CCP recipients ranged from 0.64 &#x2013; 0.67, with an upper 95&#x0025; confidence bound of 0.91 (<xref ref-type="bibr" rid="c8">8</xref>). Similarly, the large retrospective PSM study from HCA reported a 0.2&#x0025; decreased risk of mortality for every 1 unit of S/Co serology level (<xref ref-type="bibr" rid="c28">28</xref>).</p>
<p>The nAb titer (or total IgG levels as measured by surrogate assays) only describes one factor involved in defining the real therapeutic dose in that it represents the concentration of just one (likely the main) active ingredient. But CCP contains additional antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC), complement activation and phagocytosis of viral particles, functions that can each contribute to its antiviral effects (<xref ref-type="bibr" rid="c29">29</xref>). At this time the relative importance of nAbs vs. the other antibody activities is not understood, but, hopefully, retrospective analyses that correlate CCP efficacy with these activities will reveal additional variables that need to be considered in choosing optimal CCP units.</p>
<p>Despite these uncertainties, we can make estimates of likely effective doses based on the available clinical experience thus far. The therapeutic dose of nAb is a product of its concentration in the infused CP multiplied by the overall infused CP volume, adjusted to the recipient body weight to take account of dilution into the blood volume and tissues. RCTs have varied in the provision of volume per unit (200-300 ml), and most importantly in cumulative volume per patient (1-4 units) and in extent of exposure to diverse antibodies from various CCP donors, and no published trials have adjusted levels of nAbs by recipient body weight (or, when attempts have been performed, they referred to the old- fashioned 10-15 ml/kg dose inferred from treatment of hemorrhagic coagulopathies (<xref ref-type="bibr" rid="c30">30</xref>)). A failure of CCP to improve outcomes when 200-ml of 1:160 nAb-titer CCP is provided to a patient who weighs 120 kg represents quite a different scenario from failure of a 600-ml transfusion of 1:640 nAb-titer CCP to produce improvement in a 60-kg patient. But these central issues in dosage have not been considered in the RCTs published so far.</p>
<p>Several RCTs performed nAb titration, but with highly heterogenous methods which makes comparability of doses across studies difficult. <xref rid="tbl1" ref-type="table">Table 1</xref> attempts to reconcile doses across those trials, showing that they actually differed more than was apparent by inspection of raw titers. The lack of utility from low-titer (1:40) CCP in moderate COVID-19 was confirmed by the PLACID trial (<xref ref-type="bibr" rid="c10">10</xref>). As long as a clear therapeutic dose is not identified, it seems prudent to transfuse units containing nAb titers at least 10-fold higher than the nAb titer measured before transfusion in recipient serum. Similarly, the ConCOVID RCT showed that CCP units having nAb titers similar to those of the recipients (1:160) did not confer a clinical benefit (<xref ref-type="bibr" rid="c31">31</xref>). CCP units with an adequate nAb titer (nowadays estimated at <underline>&#x003E;</underline>1:160) are more easily found among older males who recovered from a previous symptomatic COVID-19 requiring hospitalization (<xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref>): unfortunately, such donors were poorly represented in the first donation waves, which tended to obtain CCP from younger donors will mild disease, and, presumably lower nAb titers (<xref ref-type="bibr" rid="c10">10</xref>).</p>
</sec>
<sec id="s3c">
<title>Relevance of CCP to the viral variant</title>
<p>Albeit not formally demonstrated, CCP manufactured by pooling ABO-matched transfusion from many different donors (e.g., in PlasmAr (<xref ref-type="bibr" rid="c12">12</xref>)) theoretically have greater polyclonality of nAbs than repeated CCP doses from a single-donor (e.g. CAPSID (<xref ref-type="bibr" rid="c34">34</xref>)) and should grant higher efficacy against viral variants. Nevertheless, pooling typically occurs among donors attending the same blood bank, making donor exposure to different viral variants unlikely.</p>
<p>An analysis of potential variables associated with CCP efficacy associated near-sourcing with reduced mortality, with the efficacy of CCP in reducing mortality falling sharply when the CCP source was more than 150 miles from where it was used (<xref ref-type="bibr" rid="c35">35</xref>). This finding suggests that SARS-CoV-2 viruses vary enough in their antigenic composition in different geographic locations to create antibody responses that differ by locale (<xref ref-type="bibr" rid="c36">36</xref>). Even though CCP is often standardized for nAb titer to the Spike protein, the VNT could use a nonrelevant viral strain, or miss major functional differences for the antibody response (<xref ref-type="bibr" rid="c29">29</xref>). This finding has implication for RCTs that use nationally sourced (centralized) CCP, since the attempt to standardize the therapeutic units centrally could inadvertently reduce CCP efficacy if hospitals use CCP obtained from distant loci. For example, in the C3PO RCT, which was conducted in 21 USA states, 95&#x0025; of the donor CCP was collected in either Chicago or Denver: since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from remote sources (<xref ref-type="bibr" rid="c23">23</xref>). By contrast, the NCT04359810 RCT in New York and Brazil used CCP locally sourced in New York, whose efficacy against P.1 was tested to ensure efficacy at the other recruiting center in Brazil (<xref ref-type="bibr" rid="c11">11</xref>).</p>
<p>Although also not formally demonstrated during clinical trials, it is also reasonable to assume that CCP collected during early pandemic waves could be less effective against currently circulating variants of concern (<xref ref-type="bibr" rid="c37">37</xref>). RCTs whose recruitment was protracted across multiple pandemic waves (e.g., ConPlas-19 and TSUNAMI) and which relied on CCP collected and banked months earlier could have inadvertently used CCP with reduced activity against the SARS-CoV-2 strains circulating the community when the therapy was administered. Hence, both geography and time of collection of the CCP are important variables when considering the efficacy of the treatment.</p>
</sec>
<sec id="s3d">
<title>The intended outcomes</title>
<p>Most trials (CONTAIN, COMPILE, and PassItOn being exceptions) have used composite endpoints or specialty scores (e.g., SOFA) rather than progression in the simple WHO ordinal scale or mortality, and many were stopped because of apparent futility at a time when they may have been underpowered to detect significant benefit. As represented in <xref rid="fig1" ref-type="fig">Figure 1</xref>, several studies have reported overall negative results (panel A) despite the presence of positive signals of efficacy just barely missing statistical significance (panels B and C). The significance level (i.e., <italic>p</italic>&#x003D; 0.05) is largely a socially constructed convention for rejecting the null hypotheses, but it has often been misinterpreted as a measure of reality by many individuals not familiar with the nuances of statistics. For example, some CCP studies have concluded that a difference that did not achieve a p value &#x003C; 0.05 was an absence of difference, even when mortality in the CCP arm was &#x223C;20-40&#x0025; lower than in controls. This reasoning played a central role in the polarized views of CCP efficacy and prevented subsequent studies to drill down on positive effects that were observed. The dogged pursuit of statistical significance, viewed as a measure of reality instead of the actual reality demonstrated by the data, during a public health emergency dealt a serious blow to studies of CCP and created significant confusion for clinicians. It is also important to understand that RCTs are powered to be less tolerant of Type I error than Type II error, which are conventionally set at .05 and .20, meaning that a Type II error is expected four times as often as a Type 1 error. This statistical convention can contribute to the absence of significance in studies that were set up early in the pandemic when there was little information on expected effects for the various patient populations studied and the patients were very heterogenous such that only subgroups may have responded. Many studies were originally designed to enroll patients at any disease stage, and it should be no surprise that subgroup analyses on the groups that were later demonstrated more likely to benefit from CCP (e.g., early treated, seronegative patients, those receiving high nAb titre) were underpowered to reach statistical significance, as shown by orange color predominance in panel C of Figure 2. Nevertheless, favorable trends are a shared feature across such trials. Lastly, rigid adherence to primary outcomes that were often fixed in the early days of the pandemic when information about disease stage and quality of CCP associated with efficacy were not understood. When these outcomes were not met, trials were considered failures even though there were often signals of efficacy in the data that were not considered as valuable since these had not been pre-specified, even when they made biological sense. For example, in the New York-Brazil RCT cited above, CCP did not lower the primary end-point of clinical status on an ordinal scale, but the statistically significant halving of mortality was acknowledged in the abstract. Would it have made sense to ignore the strong effect of CCP on mortality in this trial just because mortality was not selected as a primary outcome? Although we agree that subgroup analysis carries the risk of &#x2018;cherry picking&#x2019; data, such analyses are often important for hypothesis generation and critically important during the emergency of a pandemic where neither viral pathogenesis nor therapeutic variables are well understood. When sub-group analyses are based on firm biological principles, such as focusing on those treated early in disease or lacking their own serological response, the exercise is not cherry picking. To emphasize this point, Christopher Columbus missed the pre-specified primary endpoint of his mission - reaching India - but no one considers his discovery of the New World to be a failure! Turning to the clinical arena, most trials of anticoagulants in myocardial infarction found reductions in mortality of about 20-25&#x0025;, which was generally not significant in these underpowered trials that declared the findings to be null, even though such a mortality reduction would clearly be of value (<xref ref-type="bibr" rid="c38">38</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1</label>
<caption><p>Simplified graphical representation of CCP RCTs reported to date, plotted according to earliness of intervention and nAb titers in CCP. In <bold>panel A</bold>, green text indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint. In <bold>panel B</bold>, green text indicates trials which showed overall mortality benefit from CCP; orange text indicates trials which showed mortality benefit from CCP in the subgroup of early arrivals or higher nAb titers; red text indicates trials which failed to show any mortality benefit from CCP. In <bold>panel C</bold>, green text indicates trials which showed statistically significant mortality benefit from CCP (overall or in the subgroup of early arrivals or higher nAb titers); orange text indicates trials which showed statistical trends towards mortality benefit from CCP (overall or in the subgroup of early arrivals); red text indicates trials which failed to show any mortality benefit trend from CCP in any subgroup. Underlined text indicates large trials which were not RCT and for which nAb levels was inferred from high-throughput serology, but are nevertheless reported as reference studies. Numbers in parenthesis indicate cumulative number of patients enrolled.</p></caption>
<graphic xlink:href="21263194v1_fig1.tif"/>
</fig>
<p>Another misunderstood endpoint is viral clearance, defined as the conversion of nasopharyngeal swabs (NPS) from positive to negative for PCR evidence of SARS-CoV-2 in CCP-treated patients. While there was early and robust evidence for this effect from CCP (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c10">10</xref>), some RCTs (e.g., TSUNAMI) failed to find differences between arms just because they sampled NPS too late after CCP treatment, when the endogenous immune response had also mounted in the control arm, and differences vanished.</p>
</sec>
<sec id="s3e">
<title>Analyzing failures in individual RCTs</title>
<p>We use the word &#x2018;failures&#x2019; with care and considerable nuance, since negative trials can be very important in teaching us about populations that do not benefit from CCP or variables that affect its efficacy. Keeping the factors discussed above in mind, we have analyzed individual RCTs in detail. At the very beginning, many historically or internally controlled observational studies showed clinical benefit from CCP and this led the FDA to issue an EAP in March 2020 that was converted into an emergency use authorization (EUA) in August 23, 2020. The largest observational study is the US open-label EAP (NCT04338360) led from Joyner <italic>et al</italic>, which enrolled 105,717 hospitalized patients with severe or life-threatening COVID-19 from April 3 to August 23, 2020 (<xref ref-type="bibr" rid="c39">39</xref>). In an analysis of the effect of antibody in CCP performed independently of the results cited above (<xref ref-type="bibr" rid="c8">8</xref>) and using a nAb titer in an overlapping but non-identical group of EAP patients, the FDA showed that the 7-day mortality in non-intubated patients who were younger than 80 years of age and were treated within 72 hours after diagnosis was 6.3&#x0025; in those receiving high-titer CCP and 11.3&#x0025; in those receiving low-titer CCP (<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/142386/download">https://www.fda.gov/media/142386/download</ext-link>).</p>
<p>In a later analysis of a larger (N &#x003D; 35,322) subset of EAP patients, (including 52.3&#x0025; in the intensive care unit (ICU) and 27.5&#x0025; receiving mechanical ventilation), the 7-day mortality rate was 8.7&#x0025; in patients transfused within 3 days of diagnosis but 11.9&#x0025; in patients transfused &#x2265;4 days after diagnosis. Similar findings again from the US EAP were observed in 30-day mortality (21.6&#x0025; vs. 26.7&#x0025;) (<xref ref-type="bibr" rid="c40">40</xref>). The major criticism of these results is that controls were neither randomized nor PSM: hence a difference in the treatment outcome between treated and untreated groups may be caused by a factor that predicts treatment rather than by the treatment itself. However, importantly, nAb titer analysis was retrospectively done, both patients and physicians were unaware of the nAb content in the CCP units used, the results are what would have been expected from the experience with antibody therapy, and multivariate models were used to adjust for potential confounders (<xref ref-type="bibr" rid="c1">1</xref>). Additionally, given the outline of an optimal use case with this data and the earlier underpowered RCT by Li <italic>et al</italic> (<xref ref-type="bibr" rid="c5">5</xref>), it is unfortunate that due to (a) lack of awareness and (b) logistical burden associated with protocol adjustments, involving repowering and new patients&#x2019; recruitment criteria, later treatment RCTs either continued or initiated without modifications to include newly available evidence.</p>
<p>The highest level of scientific evidence in primary clinical research stems from prospective PSM and RCTs. PSM studies (<xref rid="tbl3" ref-type="table">Table 3</xref>) balance treatment and control groups on a large number of covariates without losing a large number of observations. Unfortunately, no PSM study to date has investigated nAb titers by VNT, and all times have been reported since hospitalization (excluding outpatients). Nevertheless, in 2 retrospective PSM studies from 2 different hospitals in New York, trends for improved outcomes in non-intubated and those treated within 7 days since hospitalization (HR 0.33) were observed (<xref ref-type="bibr" rid="c41">41</xref>, <xref ref-type="bibr" rid="c42">42</xref>). These findings were later confirmed in a prospective PSM study from Houston (<xref ref-type="bibr" rid="c43">43</xref>, <xref ref-type="bibr" rid="c44">44</xref>). Of interest, a retrospective PSM study from Providence did not show any benefit, but patients were treated at a median of 7 days after onset of symptoms (<xref ref-type="bibr" rid="c45">45</xref>). Another PSM study from Yale associated CCP with a 35&#x0025; reduction in mortality (<xref ref-type="bibr" rid="c46">46</xref>). That study is notable in that it included patients on mechanical ventilation who would not normally be expected to benefit from CCP and the percentage of individuals receiving corticosteroids was very low since the study was conducted in the early days of the pandemic in the USA. Another PSM from the Washington DC area found a reduction in mortality with CCP use at both days 14 and 28, which reached statistical significance at the earlier date (<xref ref-type="bibr" rid="c47">47</xref>). Finally, a very large study from 176 community hospitals affiliated with Healthcare Corporation of America confirmed substantial mortality reduction in hospitalized patients receiving CCP within 3 days from admission (<xref ref-type="bibr" rid="c48">48</xref>).</p>
<p>Since PSM only accounts for observed (and observable) covariates, and not latent characteristics, RCT remains the gold standard for highest-level evidence (<xref rid="tbl2" ref-type="table">Table 2</xref>). In the PlasmAr RCT, the small number of early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the CCP arm (n&#x003D; 28) compared to the placebo arm (n&#x003D;11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at day 30 (<xref ref-type="bibr" rid="c12">12</xref>). In another Argentinean RCT on 160 outpatients older than 65 years of age with mild COVID-19 who were treated with CCP within 72 hours, progression to severe COVID-19 halved at day 30 (<xref ref-type="bibr" rid="c49">49</xref>). An RCT from India reported that patients younger than 67 treated at a median of 4 days after hospital admission manifested superior mitigation of hypoxia and survival in the CCP arm (<xref ref-type="bibr" rid="c50">50</xref>). Another RCT in Spain enrolling patients at less than 7 days of hospitalization showed four deaths in the control arm, none in the CCP arm (<xref ref-type="bibr" rid="c51">51</xref>). Given that conventional peer-review slows down during a pandemic, pre-publishing RCT results by the preprint mechanism should be encouraged to accelerate sharing of potentially life-saving therapeutic approaches and to provide pre-publication review that could improve the quality of the final published study.</p>
<p><xref rid="fig1" ref-type="fig">Figure 1</xref> graphically places the outcomes of RCTs and PSM studies on a Cartesian plot having timeliness and nAbs dose as variables (if values are disclosed in the reports): this makes immediately clear that the few successes at reaching the primary endpoints have gathered into the lower right corner (high nAb dose and early intervention), while the many &#x201C;failures&#x201D; have been scattered all around (panel A), reflecting lower antibody levels infused or late treatment, or both, with the latter being the commoner problem. Nevertheless, when we focus on mortality irrespective of statistical significance (panel B) or focusing on statistical significance (panel C), many more RCTs showed clear benefits.</p>
<p>We will focus here on &#x201C;failures&#x201D; as identified by title, abstract and/or press recognition. Narratively, we could group so-called &#x201C;failures&#x201D;, with failure implying inability to demonstrate a favorable outcome to CCP use, into 4 categories, according to the main reasons:
<list list-type="order">
<list-item><p>Trials that transfused insufficient therapeutic doses of CCP due to either low total IgG levels or low nAb levels (e.g., PLACID)</p></list-item>
<list-item><p>Trials that transfused appropriate doses of CCP but too late, but which nevertheless reported signals of efficacy (e.g., RECOVERY, CAPSID, NCT04359810 and TSUNAMI)</p></list-item>
<list-item><p>Trials that were stopped too early to observe benefit or with inherent design flaws, and/or were underpowered such that likelihood of success was reduced (e.g., C3PO)</p></list-item>
<list-item><p>Trial in which CCP was used to treat a condition not amenable to antibody intervention, such as hypoxia that is caused by pulmonary inflammation (e.g., COP20)</p></list-item>
</list>
Stopping trials for futility is an occurrence that deserves special attention, because it represents wasted resources during a pandemic. Six RCTs so far have been halted for futility, namely RECOVERY, REMAP-CAP, CONCOR-1, C3PO, NCT04361253, and COP20, with the first one being to date the strongest evidence for futility (<xref ref-type="bibr" rid="c30">30</xref>), with its massive recruitment affecting the outcomes of systematic reviews (<xref ref-type="bibr" rid="c52">52</xref>). Instead of stopping trials for futility based on pre-set endpoints it makes more sense that DSMBs facing a high likelihood of lack of statistical significance provide advice on trial modifications that are likely to amplify the significance of signals of efficacy evident in these studies.</p>
<p>This would seem a more responsible action than trial cessation given the paucity of therapeutic alternatives in the pandemic emergency. Indeed, a Bayesian re-analysis of RECOVERY data with a wide variety of priors (vague, optimistic, skeptical and pessimistic) calculated the posterior probability for both any benefit or a modest benefit (number needed to treat of 100). Across all patients, when analyzed with a vague prior, the likelihood of any benefit or a modest benefit was estimated to be 64&#x0025; and 18&#x0025; respectively. In contrast, in the seronegative subgroup, the likelihood of any benefit or a modest benefit was estimated to be 90&#x0025; and 74&#x0025; (<xref ref-type="bibr" rid="c53">53</xref>). This finding of benefit accruing to specific sub-groups, who were not determined post-hoc but because they were likely to benefit based on understanding of principles of CP treatment is found in nearly every trial whose overall finding is negative.</p>
</sec>
<sec id="s3f">
<title>The inadequacy of meta-analyses</title>
<p>With all the heterogeneity in key drivers discussed in the former paragraphs, it becomes clear that secondary research (ranging from umbrella reviews to meta-analyses to systematic reviews), whereby each study is considered at the same level, invariably ends up with biased and divergent conclusions. This adds confusion to the already complex field of individual trial outcomes. Amazingly, as of August 24, 2021, PubMed has indexed 25 meta-analyses on CCP efficacy, more than the RCTs reported at the same date. Until the beginning of 2021, meta-analyses (variably including observational studies) were generally in favor of CCP (<xref ref-type="bibr" rid="c54">54</xref>), but began to be biased towards failure after publication of the large RECOVERY trial (<xref ref-type="bibr" rid="c30">30</xref>), which, by enrolling as many as 11,448 patients, diluted all the other divergent RCTs. Clear examples of this phenomenon come from a widely cited metanalysis from Janiaud <italic>et al</italic> in <italic>JAMA</italic> (<xref ref-type="bibr" rid="c52">52</xref>) which included press release data from RECOVERY and from the living systematic review by the Cochrane Group (<xref ref-type="bibr" rid="c55">55</xref>). This paper was surely unprecedented in the tradition of meta-analysis, not only because it included a study based only on a news release (which proved to differ in some important respects from the published paper), but because it allowed these data from a news release to dominate the entire analysis. Several groups attempted to dissect the RECOVERY trial and others by running subgroup analyses in their systematic reviews (<xref ref-type="bibr" rid="c53">53</xref>, <xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c57">57</xref>), but these reviews were unable to restore confidence in CCP efficacy in the clinical community that had been lost because of the publication of the overall negative findings of RECOVERY and PlasmAr (<xref ref-type="bibr" rid="c58">58</xref>). A metanalysis of 22,591 patients (enrolled in 10 RCTs and 15 observational studies) showed that early CCP significantly reduced mortality (RR 0.72, p&#x003C;0.00001), but only in patients who were not suffering severe or critical disease (<xref ref-type="bibr" rid="c59">59</xref>). On the other hand, another metanalysis of 18 peer-review clinical trials, 3 preprints, and 26 observational studies actually found that CCP use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients (<xref ref-type="bibr" rid="c60">60</xref>). A recent umbrella review of 29 metanalyses and systematic reviews found evidences for improvement in the CCP arms for some outcomes (overall mortality, viral clearance at day 3,) but not for others (clinical improvement, length of hospital stay (<xref ref-type="bibr" rid="c61">61</xref>).</p>
<p>Rather than pooling published RCTs, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) study pooled individual patient data from ongoing RCTs at two-week intervals. Unfortunately, with the single exception of CONTAIN, participating RCTs largely shared late usage (DAWN-plasma, PLACID, ConCOVID, ConPlas-19, NCT04421404, NCT04397757, and the Bras&#x00ED;lia Covid-19 Convalescent Plasma (BCCP)) (<xref ref-type="bibr" rid="c62">62</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Conclusions</title>
<p>While CCP contains a plethora of biologically active molecules (<xref ref-type="bibr" rid="c63">63</xref>), we now have very strong evidence that appropriately vetted CCP from eligible convalescent donors is safe for patients (<xref ref-type="bibr" rid="c64">64</xref>, <xref ref-type="bibr" rid="c65">65</xref>), with no evidence of increased risks of transfusion-transmitted acute lung injury, antibody-mediated enhancement concerns feared in the early days of the pandemic (<xref ref-type="bibr" rid="c66">66</xref>) nor is there evidence that CCP induces accelerated SARS-CoV-2 evolution (<xref ref-type="bibr" rid="c11">11</xref>). Polyclonal antibodies such as CCP, or CCP-derived hyperimmune globulins made from large donor pools, are likely to offer better protection against onset of variants than monoclonal antibodies. Outcomes in immunocompromised patients treated with CCP have been successful in the long-term, with minimal evidence for immune escape (<xref ref-type="bibr" rid="c67">67</xref>). There is evidence that vaccinated convalescents may have even higher nAb titers than unvaccinated convalescents offering the promise of expanded success in using CCP (<xref ref-type="bibr" rid="c68">68</xref>).</p>
<p>We have also learned that CCP is less likely to benefit patients requiring oxygen (i.e., from level 4 and up on the 11-point WHO ordinal scale), and hence, ideally, the focus should be on outpatients and in identifying that subset of patients who seek hospital care and are still sufficiently early in the course of disease such that they can benefit from CCP. This finding parallels the finding with hyperimmune serum and anti-Spike monoclonal antibodies, which at first failed in hospitalized patients (<xref ref-type="bibr" rid="c69">69</xref>, <xref ref-type="bibr" rid="c70">70</xref>), but later succeeded for ambulatory patients with mild to moderate COVID-19 (<xref ref-type="bibr" rid="c71">71</xref>) and were approved for emergency use. However, at this moment clinical use in the US is restricted by the FDA to inpatients.</p>
<p>CCP usage per admission peaked after issuance of the EUA, with more than 40&#x0025; of inpatients estimated to have received CCP between late September and early November 2020. However, following reports of RCTs that failed to show clear benefit from CCP, usage per admissions declined steadily to a nadir of less than 10&#x0025; in March 2021. A strong inverse correlation (Pearson correlation coefficient of -0.5176 with P &#x003D; 0.00242) was found between CCP usage/hospital admission and deaths occurring 2 weeks after admission, and this finding was robust to examination of deaths taking place 1, 2 or 3 weeks after admission. Changes in the number of hospital admissions, prevalence of variants, and age of patients could not explain these findings. The authors estimated that the retreat from CCP usage, a phenomenon they termed &#x201C;plasma hesitancy&#x201D;, might have resulted in 29,000 to 36,000 excess deaths in the period from mid-November 2020 to February 2021 (<xref ref-type="bibr" rid="c72">72</xref>). The same analysis estimated that USA had avoided 96,000 excess deaths from August 2020 to March 2021 by its liberal deployment of CCP.</p>
<p>Several lines of evidence, ranging from the EAP to clinical trials employing RCT or PSM controls are now indicating how CCP should be used in immunocompetent patients (<xref ref-type="bibr" rid="c73">73</xref>). The evidence supports the initiation of CCP treatment as early as 44-72 hours within onset of symptoms (which largely pertains to outpatients) and using CCP with a nAb titer &#x003E; 1:160. Benefit within 1 week from onset of symptoms (including in hospitalized patients) is less well understood, although a benefit from higher therapeutic doses cannot be ruled out at this stage. Clinical benefit seems absent when administered after 1 week from onset of symptoms or in patients requiring ventilation, or in those who receive CCP with a low nAb titer. Nevertheless, chronically immunosuppressed patients benefit from CCP even at later stages (<xref ref-type="bibr" rid="c67">67</xref>, <xref ref-type="bibr" rid="c74">74</xref>, <xref ref-type="bibr" rid="c75">75</xref>) : the best evidence for this scenario comes from a prospective PSM showing a halving of mortality in ICU-admitted oncohematological COVID-19 patients who received CCP (<xref ref-type="bibr" rid="c76">76</xref>). We note that while there have been concerns that use in immuncompromised can promote the emergence of antibody-resistant variants, such variants have emerged from massive replication in susceptible populations and not from treated patients, who in any case are isolated in hospitals where mitigation efforts to reduce transmission are employed, and are thus very unlikely to transmit their viruses further (<xref ref-type="bibr" rid="c77">77</xref>). Such simple concepts have been poorly communicated to the general public and the clinical community, who should be better informed of the state of current evidence that support CCP efficacy.</p>
<sec id="s4a">
<title>The future of CCP</title>
<p>CCP remains a relatively inexpensive therapy that is available throughout the world even in resource poor areas that cannot afford expensive antiviral drugs or monoclonal antibody therapies. Much has been learned about the variables that affect CCP efficacy even though, as recounted here, the clinical efficacy data is mixed. <xref rid="tbl4" ref-type="table">Table 4</xref> lists the RCTs whose outcomes have still to be reported after completion or which are still recruiting patients. Unfortunately, little new can be expected given that most of these RCTs were designed to enroll patients having symptoms for more than 7 days. Given the heterogeneity of the product and the complex variables that contribute to efficacy it is remarkable that many studies have reported reductions in mortality. This suggests a robust therapeutic effect that allow signals of efficacy to break through all the noise imposed by variability in the product and its clinical use. The positive evidence for CCP efficacy cannot be dismissed while negative results can be explained. In the absence of good therapeutic options for COVID-19, CCP is likely to find a niche in the early treatment of disease. Instead of looking for unlikely superiority outcomes, noninferiority RCTs comparing monoclonal antibody versus CCP in early arrivals should be initiated. Such an RCT is very unlikely to be sponsored by vendor companies, so public institutions should be sensitized to funding it.</p>
<p>Given the experience accumulated with COVID-19, it is almost certain that CP will again be deployed for the next epidemic and we are hopeful that lessons learned in this pandemic are heeded such that use and trials focus on the very early use with high-titer CP.</p>
<p>We declare we have no conflict of interest to disclose.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All data are available via request to the corresponding author</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19</article-title>. <source>mBio</source> <volume>12</volume>:<fpage>e03372</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>L</given-names></string-name>-a. <year>2020</year>. <article-title>The convalescent sera option for containing COVID-19</article-title>. <source>The Journal of Clinical Investigation</source> <volume>130</volume>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Luke</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Watowich</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Hoffman</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Beigel</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Burgess</surname> <given-names>TH</given-names></string-name>. <year>2010</year>. <article-title>Hark back: passive immunotherapy for influenza and other serious infections</article-title>. <source>Crit Care Med</source> <volume>38</volume>:<fpage>e66</fpage>&#x2013;<lpage>73</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Duan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Qu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>B</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>W</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>K</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Gong</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>X</given-names></string-name>. <year>2020</year>. <article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title>. <source>Proceedings of the National Academy of Sciences</source> doi:<pub-id pub-id-type="doi">10.1073/pnas.2004168117:202004168</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tong</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kong</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ren</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Mei</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Man</surname> <given-names>N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Su</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>. <year>2020</year>. <article-title>Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life- threatening COVID-19: A Randomized Clinical Trial</article-title>. <source>JAMA</source> <volume>324</volume>:<fpage>460</fpage>&#x2013;<lpage>470</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Perotti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Baldanti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>R</given-names></string-name>, <string-name><surname>Delfante</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seminari</surname> <given-names>E</given-names></string-name>, <string-name><surname>Casari</surname> <given-names>S</given-names></string-name>, <string-name><surname>Percivalle</surname> <given-names>E</given-names></string-name>, <string-name><surname>Glingani</surname> <given-names>C</given-names></string-name>, <string-name><surname>Musella</surname> <given-names>V</given-names></string-name>, <string-name><surname>Belliato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Garuti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Meloni</surname> <given-names>F</given-names></string-name>, <string-name><surname>Frigato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Di Sabatino</surname> <given-names>A</given-names></string-name>, <string-name><surname>Klersy</surname> <given-names>C</given-names></string-name>, <string-name><surname>De Donno</surname> <given-names>G</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M.</given-names></string-name> <year>2020</year>. <article-title>Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial</article-title>. <source>Haematologica</source> <volume>105</volume>:<fpage>2834</fpage>&#x2013;<lpage>2840</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>AO</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Tuccori</surname> <given-names>M</given-names></string-name>. <year>2020</year>. <article-title>Convalescent Plasma Therapy for COVID- 19: State of the Art</article-title>. <source>Clin Microbiol Rev</source> <volume>33</volume>:<fpage>e00072</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Spiegel</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Lesser</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Hodge</surname> <given-names>DO</given-names></string-name>, <string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>van Buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Verdun</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>P</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>. <year>2020</year>. <article-title>Early safety indicators of COVID-19 convalescent plasma in 5,000 patients</article-title>. <source>J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1172/jci140200</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Mills</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Theel</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lesser</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Diaz Soto</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JRA</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Verdun</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>P</given-names></string-name>, <string-name><surname>van Buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Hodge</surname> <given-names>DO</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MNP</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A.</given-names></string-name> <year>2021</year>. <article-title>Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19</article-title>. <source>N Engl J Med</source> <volume>384</volume>:<fpage>1015</fpage>&#x2013;<lpage>1027</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Agarwal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mukherjee</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>G</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bhatnagar</surname> <given-names>T</given-names></string-name>, <string-name><surname>Malhotra</surname> <given-names>P</given-names></string-name>, <string-name><surname>Latha</surname> <given-names>B</given-names></string-name>, <string-name><surname>Bundas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dosi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Khambholja</surname> <given-names>JK</given-names></string-name>, <string-name><surname>de Souza</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mesipogu</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Srivastava</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dube</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chaudhary K</surname>, <given-names>S S</given-names></string-name>, <string-name><surname>Mattuvar K</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Rajendran</surname> <given-names>V</given-names></string-name>, <string-name><surname>Sundararajaperumal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Balamanikandan</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maheswari</surname> <given-names>RSU</given-names></string-name>, <string-name><surname>Jayanthi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ragunanthanan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bhandari</surname> <given-names>S</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Handa</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rankawat</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kargirwar</surname> <given-names>K</given-names></string-name>, <string-name><surname>Regi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rathod</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pathrose</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bhutaka</surname> <given-names>N</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Malukani</surname> <given-names>K</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thakur</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joshi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kulkarni</surname> <given-names>R</given-names></string-name>, <string-name><surname>Suthar</surname> <given-names>NN</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Purohit</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>CK</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Memon</surname> <given-names>T</given-names></string-name>, <string-name><surname>Beriwala</surname> <given-names>VR</given-names></string-name>, <etal>et al.</etal> <year>2020</year>. <article-title>Convalescent plasma in the management of moderate COVID-19 in India: open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)</article-title>. <source>BMJ</source> <volume>371</volume>:<fpage>m3939</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>O&#x2019;Donnell</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Grinsztejn</surname> <given-names>B</given-names></string-name>, <string-name><surname>Cummings</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Justman</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lamb</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Eckhardt</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Philip</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Cheung</surname> <given-names>YK</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>V</given-names></string-name>, <string-name><surname>Jo&#x00E3;o</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pilotto</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Diniz</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Cardoso</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Abrams</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rajagopalan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Borden</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wolf</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sidi</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Vizzoni</surname> <given-names>A</given-names></string-name>, <string-name><surname>Veloso</surname> <given-names>VG</given-names></string-name>, <string-name><surname>Bitan</surname> <given-names>ZC</given-names></string-name>, <string-name><surname>Scotto</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Jacobson</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Kantor</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mishra</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chauhan</surname> <given-names>LV</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>E</given-names></string-name>, <string-name><surname>Dei Zotti</surname> <given-names>F</given-names></string-name>, <string-name><surname>La Carpia</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hudson</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Ferrera</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Stotler</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>W-H</given-names></string-name>, <string-name><surname>Wontakal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shaz</surname> <given-names>B</given-names></string-name>, <string-name><surname>Briese</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hod</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Spitalnik</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Eisenberger</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lipkin</surname> <given-names>WI</given-names></string-name>. <year>2021</year>. <article-title>A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19</article-title>. <source>J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1172/JCI150646:150646</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Simonovich</surname> <given-names>VA</given-names></string-name>, <string-name><surname>Burgos Pratx</surname> <given-names>LD</given-names></string-name>, <string-name><surname>Scibona</surname> <given-names>P</given-names></string-name>, <string-name><surname>Beruto</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Vallone</surname> <given-names>MG</given-names></string-name>, <string-name><surname>V&#x00E1;zquez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Savoy</surname> <given-names>N</given-names></string-name>, <string-name><surname>Giunta</surname> <given-names>DH</given-names></string-name>, <string-name><surname>P&#x00E9;rez</surname> <given-names>LG</given-names></string-name>, <string-name><given-names>S&#x00E1;nchez</given-names> <surname>MdL</surname></string-name>, <string-name><surname>Gamarnik</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Ojeda</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Santoro</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Camino</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Antelo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rainero</surname> <given-names>K</given-names></string-name>, <string-name><surname>Vidiella</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Miyazaki</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Cornistein</surname> <given-names>W</given-names></string-name>, <string-name><surname>Trabadelo</surname> <given-names>OA</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Spotti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Funtowicz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Scordo</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Losso</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Ferniot</surname> <given-names>I</given-names></string-name>, <string-name><surname>Pardo</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Rodriguez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rucci</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pasquali</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fuentes</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Esperatti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Speroni</surname> <given-names>GA</given-names></string-name>, <string-name><surname>Nannini</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Matteaccio</surname> <given-names>A</given-names></string-name>, <string-name><surname>Michelangelo</surname> <given-names>HG</given-names></string-name>, <string-name><surname>Follmann</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lane</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Belloso</surname> <given-names>WH</given-names></string-name>. <year>2020</year>. <article-title>A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia</article-title>. <source>N Engl J Med</source> <volume>384</volume>:<fpage>619</fpage>&#x2013;<lpage>629</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>. <year>2020</year>. <article-title>Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework</article-title>. <source>mBio</source> <volume>11</volume>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Van Rompay</surname> <given-names>KKA</given-names></string-name>, <string-name><surname>Olstad</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Sammak</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Dutra</surname> <given-names>J</given-names></string-name>, <string-name><surname>Watanabe</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Usachenko</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Immareddy</surname> <given-names>R</given-names></string-name>, <string-name><surname>Roh</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lakshmanappa</surname> <given-names>YS</given-names></string-name>, <string-name><surname>Schmidt</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Germanio</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Rizvi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>M</given-names></string-name>, <string-name><surname>Simmons</surname> <given-names>G</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lockwood</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pollard</surname> <given-names>RE</given-names></string-name>, <string-name><surname>de Assis</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Yee</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Nham</surname> <given-names>PB</given-names></string-name>, <string-name><surname>Ardeshir</surname> <given-names>A</given-names></string-name>, <string-name><surname>Deere</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Patterson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jain</surname> <given-names>A</given-names></string-name>, <string-name><surname>Felgner</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Iyer</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Hartigan-O&#x2019;Connor</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Busch</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Reader</surname> <given-names>JR</given-names></string-name>. <year>2021</year>. <article-title>Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation</article-title>. doi:<pub-id pub-id-type="doi">10.1101/2021.09.01.458520</pub-id> &#x0025;J <source>bioRxiv</source>:2021.09.01.458520.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Maggi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Aguzzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lanza</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mazzoni</surname> <given-names>A</given-names></string-name>, <string-name><surname>Menichetti</surname> <given-names>F</given-names></string-name>. <year>2021</year>. <article-title>Patient- blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies</article-title>. <source>Clin Microbiol Infect</source> doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2021.04.003</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Alamgir</surname> <given-names>J</given-names></string-name>, <string-name><surname>Abid</surname> <given-names>R</given-names></string-name>, <string-name><surname>Garibaldi</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Munir</surname> <given-names>N</given-names></string-name>, <string-name><surname>Setoguchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hong</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Kocis</surname> <given-names>PT</given-names></string-name>, <string-name><surname>Yajima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>GC</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>HB</given-names></string-name>, <string-name><surname>Madhira</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ergas</surname> <given-names>R</given-names></string-name>, <string-name><surname>O&#x2019;Brien</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Bozzette</surname> <given-names>S</given-names></string-name>. <year>2021</year>. <article-title>Lack of association between convalescent plasma administration and length of hospital stay: a hospital-day stratified multi-center retrospective cohort study</article-title>. <source>medrXiv [Preprint</source>] doi:<pub-id pub-id-type="doi">10.1101/2021.05.04.21256627</pub-id> &#x0025;J medRxiv:2021.05.04.21256627.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Kocayi&#x011F;it</surname> <given-names>H</given-names></string-name>, <string-name><surname>Demir</surname> <given-names>G</given-names></string-name>, <string-name><surname>Karacan</surname> <given-names>A</given-names></string-name>, <string-name><surname>S&#x00FC;ner</surname> <given-names>K</given-names></string-name>, <string-name><surname>Tomak</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yaylac&#x0131;</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dheir</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kalpakci</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Erdem</surname> <given-names>AF</given-names></string-name>. <year>2021</year>. <article-title>Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19</article-title>. <source>Transfus Apher Sci</source> doi:<pub-id pub-id-type="doi">10.1016/j.transci.2021.103148:103148</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Navarro</surname> <given-names>D</given-names></string-name>, <string-name><surname>Maggi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Roilides</surname> <given-names>E</given-names></string-name>, <string-name><surname>Antonelli</surname> <given-names>G</given-names></string-name>. <year>2021</year>. <article-title>COVID-19 infodemics: the role of mainstream and social media</article-title>. <source>Clin Microbiol Infect</source> doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2021.08.003</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="other">19. <string-name><surname>Harrell</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lindsell</surname> <given-names>C.</given-names></string-name> <year>2021</year>. <source>Statistical Design and Analysis Plan for Sequential Parallel-Group RCT for COVID-19</source>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Borobia</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Carcas</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>P&#x00E9;rez-Olmeda</surname> <given-names>M</given-names></string-name>, <string-name><surname>Casta&#x00F1;o</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bertran</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-P&#x00E9;rez</surname> <given-names>J</given-names></string-name>, <string-name><surname>Campins</surname> <given-names>M</given-names></string-name>, <string-name><surname>Portol&#x00E9;s</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gonz&#x00E1;lez-P&#x00E9;rez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Garc&#x00ED;a Morales</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Arana-Arri</surname> <given-names>E</given-names></string-name>, <string-name><surname>Aldea</surname> <given-names>M</given-names></string-name>, <string-name><surname>D&#x00ED;ez-Fuertes</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fuentes</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ascaso</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lora</surname> <given-names>D</given-names></string-name>, <string-name><surname>Imaz-Ayo</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bar&#x00F3;n-Mira</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Agust&#x00ED;</surname> <given-names>A</given-names></string-name>, <string-name><surname>P&#x00E9;rez-Ingidua</surname> <given-names>C</given-names></string-name>, <string-name><given-names>G&#x00F3;mez</given-names> <surname>de la C&#x00E1;mara A</surname></string-name>, <string-name><surname>Arribas</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Ochando</surname> <given-names>J</given-names></string-name>, <string-name><surname>Alcam&#x00ED;</surname> <given-names>J</given-names></string-name>, <string-name><surname>Belda-Iniesta</surname> <given-names>C</given-names></string-name>, <string-name><surname>Fr&#x00ED;as</surname> <given-names>J</given-names></string-name>. <year>2021</year>. <article-title>Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial</article-title>. <source>Lancet</source> <volume>398</volume>:<fpage>121</fpage>&#x2013;<lpage>130</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="website">21. <collab>WHO</collab>. <year>2020</year>. <source>R &#x0026; D Blueprint - novel Coronavirus COVID19 Therapeutic Trial Synopsis</source>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1">https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1</ext-link>. Accessed <date-in-citation content-type="access-date">October 1</date-in-citation>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><collab>Anonymous</collab>. <year>2020</year>. <article-title>A minimal common outcome measure set for COVID-19 clinical research</article-title>. <source>Lancet Infect Dis</source> <volume>20</volume>:<fpage>e192</fpage>&#x2013;<lpage>e197</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Korley</surname> <given-names>FK</given-names></string-name>, <string-name><surname>Durkalski-Mauldin</surname> <given-names>V</given-names></string-name>, <string-name><surname>Yeatts</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Schulman</surname> <given-names>K</given-names></string-name>, <string-name><surname>Davenport</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>El Kassar</surname> <given-names>N</given-names></string-name>, <string-name><surname>Foster</surname> <given-names>LD</given-names></string-name>, <string-name><surname>Hah</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Jaiswal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kaplan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lowell</surname> <given-names>E</given-names></string-name>, <string-name><surname>McDyer</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Triulzi</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Van Huysen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Stevenson</surname> <given-names>VLW</given-names></string-name>, <string-name><surname>Yadav</surname> <given-names>K</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Kea</surname> <given-names>B</given-names></string-name>, <string-name><surname>Burnett</surname> <given-names>A</given-names></string-name>, <string-name><surname>Reynolds</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Greineder</surname> <given-names>CF</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Beiser</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Silbergleit</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barsan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Callaway</surname> <given-names>CW</given-names></string-name>. <year>2021</year>. <article-title>Early Convalescent Plasma for High-Risk Outpatients with Covid-19</article-title>. <source>N Engl J Med</source> doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2103784</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Epstein</surname> <given-names>J</given-names></string-name>, <string-name><surname>Burnouf</surname> <given-names>T</given-names></string-name>. <year>2020</year>. <article-title>Points to consider in the preparation and transfusion of COVID-19 convalescent plasma</article-title>. <source>Vox Sang</source> <volume>115</volume>:<fpage>485</fpage>&#x2013;<lpage>487</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mazzetti</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pistello MM</surname>, <given-names>F</given-names></string-name>. <year>2020</year>. <article-title>Viral infection neutralization tests: a focus on SARS-CoV-2 with implications for convalescent plasma therapy</article-title>. <source>Rev Med Virol</source> doi:<pub-id pub-id-type="doi">10.1002/rmv.2170:e2170</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Nguyen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Simmonds</surname> <given-names>P</given-names></string-name>, <string-name><surname>Steenhuis</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wouters</surname> <given-names>E</given-names></string-name>, <string-name><surname>Desmecht</surname> <given-names>D</given-names></string-name>, <string-name><surname>Garigliany</surname> <given-names>M</given-names></string-name>, <string-name><surname>Romano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Barbezange</surname> <given-names>C</given-names></string-name>, <string-name><surname>Maes</surname> <given-names>P</given-names></string-name>, <string-name><surname>Van Holm</surname> <given-names>B</given-names></string-name>, <string-name><surname>Mendoza</surname> <given-names>J</given-names></string-name>, <string-name><surname>Oyonarte</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fomsgaard</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lassauni&#x00E8;re</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zusinaite</surname> <given-names>E</given-names></string-name>, <string-name><surname>Resman Rus</surname> <given-names>K</given-names></string-name>, <string-name><surname>Av&#x0161;i&#x010D;-&#x017D;upanc</surname> <given-names>T</given-names></string-name>, <string-name><surname>Reimerink</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Brouwer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hoogerwerf</surname> <given-names>M</given-names></string-name>, <string-name><surname>Reusken</surname> <given-names>CB</given-names></string-name>, <string-name><surname>Grodeland</surname> <given-names>G</given-names></string-name>, <string-name><surname>Le Cam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gallian</surname> <given-names>P</given-names></string-name>, <string-name><surname>Amroun</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brisbarre</surname> <given-names>N</given-names></string-name>, <string-name><surname>Martinaud</surname> <given-names>C</given-names></string-name>, <string-name><surname>Leparc Goffart</surname> <given-names>I</given-names></string-name>, <string-name><surname>Schrezenmeier</surname> <given-names>H</given-names></string-name>, <string-name><surname>Feys</surname> <given-names>HB</given-names></string-name>, <string-name><surname>van der Schoot</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Harvala</surname> <given-names>H</given-names></string-name>. <year>2021</year>. <article-title>SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data</article-title>. <source>Euro Surveill</source> <volume>26</volume>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Klingler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Weiss</surname> <given-names>S</given-names></string-name>, <string-name><surname>Itri</surname> <given-names>V</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Oguntuyo</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ikegame</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hung</surname> <given-names>C-T</given-names></string-name>, <string-name><surname>Enyindah- Asonye</surname> <given-names>G</given-names></string-name>, <string-name><surname>Amanat</surname> <given-names>F</given-names></string-name>, <string-name><surname>Baine</surname> <given-names>I</given-names></string-name>, <string-name><surname>Arinsburg</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bandres</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Kojic</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Stoever</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jurczyszak</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bermudez-Gonzalez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Simon</surname> <given-names>V</given-names></string-name>, <string-name><surname>N&#x00E1;das</surname> <given-names>A</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>B</given-names></string-name>, <string-name><surname>Krammer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zolla-Pazner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hioe</surname> <given-names>CE</given-names></string-name>. <year>2020</year>. <article-title>Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2</article-title>. <source>medrXiv [Preprint</source>] doi:<pub-id pub-id-type="doi">10.1101/2020.08.18.20177303</pub-id> &#x0025;J medRxiv:2020.08.18.20177303.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Egloff</surname> <given-names>SAA</given-names></string-name>, <string-name><surname>Junglen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Restivo</surname> <given-names>JSA</given-names></string-name>, <string-name><surname>Wongskhaluang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Doshi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schlauch</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fromell</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sears</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Correll</surname> <given-names>M</given-names></string-name>, <string-name><surname>Burris</surname> <given-names>HA</given-names></string-name>, <string-name><surname>LeMaistre</surname> <given-names>CF</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19</article-title>. <source>J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1172/JCI151788</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Natarajan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Crowley</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Butler</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Weiner</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Bloch</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Littlefield</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wieland-Alter</surname> <given-names>W</given-names></string-name>, <string-name><surname>Connor</surname> <given-names>RI</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>PF</given-names></string-name>, <string-name><surname>Benner</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Bonny</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Laeyendecker</surname> <given-names>O</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shoham</surname> <given-names>S</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Larman</surname> <given-names>HB</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pekosz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Redd</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Tobian</surname> <given-names>AAR</given-names></string-name>, <string-name><surname>Ackerman</surname> <given-names>ME</given-names></string-name>. <year>2021</year>. <article-title>Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma</article-title>. <source>mBio</source> <volume>12</volume>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Horby</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Estcourt</surname> <given-names>L</given-names></string-name>, <string-name><surname>Peto</surname> <given-names>L</given-names></string-name>, <string-name><surname>Emberson</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Staplin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Spata</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pessoa-Amorim</surname> <given-names>G</given-names></string-name>, <string-name><surname>Campbell</surname> <given-names>M</given-names></string-name>, <string-name><surname>Roddick</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brunskill</surname> <given-names>NE</given-names></string-name>, <string-name><surname>George</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zehnder</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tiberi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Aung</surname> <given-names>NN</given-names></string-name>, <string-name><surname>Uriel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Widdrington</surname> <given-names>J</given-names></string-name>, <string-name><surname>Koshy</surname> <given-names>G</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>T</given-names></string-name>, <string-name><surname>Scott</surname> <given-names>S</given-names></string-name>, <string-name><surname>Baillie</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Buch</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Chappell</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Day</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Faust</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Jaki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jeffery</surname> <given-names>K</given-names></string-name>, <string-name><surname>Juszczak</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Montgomery</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mumford</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rowan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Thwaites</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mafham</surname> <given-names>M</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>D</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>R</given-names></string-name>, <string-name><surname>Landray</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</article-title>. <source>Lancet</source> <volume>397</volume>:<fpage>2049</fpage>&#x2013;<lpage>2059</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Gharbharan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jordans</surname> <given-names>CCE</given-names></string-name>, <string-name><surname>GeurtsvanKessel</surname> <given-names>C</given-names></string-name>, <string-name><surname>den Hollander</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Karim</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mollema</surname> <given-names>FPN</given-names></string-name>, <string-name><surname>Stalenhoef</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Dofferhoff</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ludwig</surname> <given-names>I</given-names></string-name>, <string-name><surname>Koster</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hassing</surname> <given-names>R-J</given-names></string-name>, <string-name><surname>Bos</surname> <given-names>JC</given-names></string-name>, <string-name><surname>van Pottelberge</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Vlasveld</surname> <given-names>IN</given-names></string-name>, <string-name><surname>Ammerlaan</surname> <given-names>HSM</given-names></string-name>, <string-name><surname>Segarceanu</surname> <given-names>E</given-names></string-name>, <string-name><surname>Miedema</surname> <given-names>J</given-names></string-name>, <string-name><surname>van der Eerden</surname> <given-names>M</given-names></string-name>, <string-name><surname>Papageorgiou</surname> <given-names>G</given-names></string-name>, <string-name><surname>te Broekhorst</surname> <given-names>P</given-names></string-name>, <string-name><surname>Swaneveld</surname> <given-names>FH</given-names></string-name>, <string-name><surname>Katsikis</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Mueller</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Okba</surname> <given-names>NMA</given-names></string-name>, <string-name><surname>Koopmans</surname> <given-names>MPG</given-names></string-name>, <string-name><surname>Haagmans</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Rokx</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rijnders</surname> <given-names>B</given-names></string-name>. <year>2021</year>. <article-title>Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection</article-title>. <source>Nat Comm</source> <volume>12</volume>:<fpage>3189</fpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Del Fante</surname> <given-names>C</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baldanti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Percivalle</surname> <given-names>E</given-names></string-name>, <string-name><surname>Glingani</surname> <given-names>C</given-names></string-name>, <string-name><surname>Marano</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mengoli</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mortellaro</surname> <given-names>C</given-names></string-name>, <string-name><surname>Viarengo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Perotti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liumbruno</surname> <given-names>GM</given-names></string-name>. <year>2020</year>. <article-title>A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations</article-title>. <source>Transfusion</source> <volume>61</volume>:<fpage>830</fpage>&#x2013;<lpage>838</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Mehew</surname> <given-names>J</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>R</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>D</given-names></string-name>, <string-name><surname>Harvala</surname> <given-names>H</given-names></string-name>. <year>2020</year>. <article-title>Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020</article-title>. <source>Euro Surveill</source> <volume>25</volume>:<fpage>2001754</fpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Koerper</surname> <given-names>S</given-names></string-name>, <string-name><surname>Weiss</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zickler</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wiesmann</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zacharowski</surname> <given-names>K</given-names></string-name>, <string-name><surname>Corman</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Gruener</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ernst</surname> <given-names>L</given-names></string-name>, <string-name><surname>Spieth</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lepper</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Bentz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zinn</surname> <given-names>S</given-names></string-name>, <string-name><surname>Paul</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kalbhenn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dollinger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rosenberger</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kirschning</surname> <given-names>T</given-names></string-name>, <string-name><surname>Thiele</surname> <given-names>T</given-names></string-name>, <string-name><surname>Appl</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Schmidt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Drosten</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wulf</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kruse</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Jungwirth</surname> <given-names>B</given-names></string-name>, <string-name><surname>Seifried</surname> <given-names>E</given-names></string-name>, <string-name><surname>Schrezenmeier</surname> <given-names>H</given-names></string-name>. <year>2021</year>. <article-title>Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients</article-title>. <source>J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1172/JCI152264:2021.05.10.21256192</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Mills</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Theel</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Golafshar</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Diaz Soto</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JRA</given-names></string-name>, <string-name><surname>Verdun</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>P</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>van Buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Senese</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Pletsch</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Buchholtz</surname> <given-names>ZA</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Lesser</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MNP</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors</article-title>. <source>Nat Commun</source> <volume>12</volume>:<fpage>4864</fpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Rochman</surname> <given-names>ND</given-names></string-name>, <string-name><surname>Wolf</surname> <given-names>YI</given-names></string-name>, <string-name><surname>Faure</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mutz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Koonin</surname> <given-names>EV</given-names></string-name>. <year>2021</year>. <article-title>Ongoing global and regional adaptive evolution of SARS-CoV-2</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>118</volume>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="other"><string-name><surname>Junker</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dulovic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Becker</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wagner</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Traenkle</surname> <given-names>B</given-names></string-name>, <string-name><surname>Rothbauer</surname> <given-names>U</given-names></string-name>, <string-name><surname>Kienzle</surname> <given-names>K</given-names></string-name>, <string-name><surname>Bunk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Str&#x00FC;mper</surname> <given-names>C</given-names></string-name>, <string-name><surname>H&#x00E4;berle</surname> <given-names>H</given-names></string-name>, <string-name><surname>Schmauder</surname> <given-names>K</given-names></string-name>, <string-name><surname>Malek</surname> <given-names>N</given-names></string-name>, <string-name><surname>Althaus</surname> <given-names>K</given-names></string-name>, <string-name><surname>Koeppen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bitzer</surname> <given-names>M</given-names></string-name>, <string-name><surname>G&#x00F6;pel</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schneiderhan-Marra</surname> <given-names>N</given-names></string-name>. <year>2021</year>. <article-title>Reduced serum neutralization capacity against SARS- CoV-2 variants in a multiplex ACE2 RBD competition assay</article-title>. doi:<pub-id pub-id-type="doi">10.1101/2021.08.20.21262328</pub-id>&#x0025;J medRxiv:2021.08.20.21262328.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Chalmers</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Matta</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>H</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Kunzler</surname> <given-names>AM</given-names></string-name>. <year>1977</year>. <article-title>Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction</article-title>. <source>N Engl J Med</source> <volume>297</volume>:<fpage>1091</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Golafshar</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Diaz Soto</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JRA</given-names></string-name>, <string-name><surname>Verdun</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>P</given-names></string-name>, <string-name><surname>van Buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MNP</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>K</given-names></string-name>, <string-name><surname>Greenshields</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma</article-title>. <source>medrXiv [Preprint</source>] doi:<pub-id pub-id-type="doi">10.1101/2021.04.08.21255115</pub-id> &#x0025;J medRxiv:2021.04.08.21255115.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Mills</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Theel</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lesser</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Diaz Soto</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JRA</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>van Buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Hodge</surname> <given-names>DO</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MNP</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>. <year>2020</year>. <article-title>Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience</article-title>. <source>medRxiv</source> doi:<pub-id pub-id-type="doi">10.1101/2020.08.12.20169359</pub-id> &#x0025;J medRxiv:2020.08.12.20169359.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><given-names>Yoon</given-names> <surname>Ha</surname></string-name>, <string-name><surname>Bartash</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gendlina</surname> <given-names>I</given-names></string-name>, <string-name><surname>Rivera</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nakouzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bortz</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Wirchnianski</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Paroder</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fehn</surname> <given-names>K</given-names></string-name>, <string-name><surname>Serrano-Rahman</surname> <given-names>L</given-names></string-name>, <string-name><surname>Babb</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sarwar</surname> <given-names>UN</given-names></string-name>, <string-name><surname>Haslwanter</surname> <given-names>D</given-names></string-name>, <string-name><surname>Laudermilch</surname> <given-names>E</given-names></string-name>, <string-name><surname>Florez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dieterle</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Jangra</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Fels</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Tong</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mariano</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Vergnolle</surname> <given-names>O</given-names></string-name>, <string-name><surname>Georgiev</surname> <given-names>GI</given-names></string-name>, <string-name><surname>Herrera</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Malonis</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Quiroz</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Morano</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Krause</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Sweeney</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Cowman</surname> <given-names>K</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Annam</surname> <given-names>J</given-names></string-name>, <string-name><surname>Applebaum</surname> <given-names>A</given-names></string-name>, <string-name><surname>Barboto</surname> <given-names>D</given-names></string-name>, <string-name><surname>Khokhar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lally</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>M</given-names></string-name>, <string-name><surname>Malaviya</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sample</surname> <given-names>R</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>XA</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Thota</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barnhill</surname> <given-names>J</given-names></string-name>, <string-name><surname>Goldstein</surname> <given-names>DY</given-names></string-name>, <string-name><surname>Uehlinger</surname> <given-names>J</given-names></string-name>, <string-name><surname>Garforth</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Almo</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Gil</surname> <given-names>MR</given-names></string-name>, <etal>et al.</etal> <year>2021</year>. <article-title>Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx</article-title>, <source>NYC. JCI Insight</source> doi:<pub-id pub-id-type="doi">10.1172/jci.insight.142270:142270</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname> <given-names>STH</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>H-M</given-names></string-name>, <string-name><surname>Baine</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wajnberg</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gumprecht</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Rahman</surname> <given-names>F</given-names></string-name>, <string-name><surname>Rodriguez</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tandon</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bassily-Marcus</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bander</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sanky</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dupper</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>FT</given-names></string-name>, <string-name><surname>Amanat</surname> <given-names>F</given-names></string-name>, <string-name><surname>Stadlbauer</surname> <given-names>D</given-names></string-name>, <string-name><surname>Altman</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Krammer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mendu</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Firpo-Betancourt</surname> <given-names>A</given-names></string-name>, <string-name><surname>Levin</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Bagiella</surname> <given-names>E</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cordon-Cardo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jhang</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Arinsburg</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Reich</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Aberg</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Bouvier</surname> <given-names>NM</given-names></string-name>. <year>2020</year>. <article-title>Convalescent plasma treatment of severe COVID-19: a propensity score&#x2013;matched control study</article-title>. <source>Nature Medicine</source> <volume>26</volume>:<fpage>1708</fpage>&#x2013;<lpage>1713</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal">43. <string-name><surname>Salazar</surname> <given-names>E</given-names></string-name>, <string-name><surname>Christensen</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Graviss</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Castillo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lopez</surname> <given-names>BV</given-names></string-name>, <string-name><surname>Eagar</surname> <given-names>TN</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>P</given-names></string-name>, <string-name><surname>Rogers</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shehabeldin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joseph</surname> <given-names>D</given-names></string-name>, <string-name><surname>Leveque</surname> <given-names>C</given-names></string-name>, <string-name><surname>Olsen</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bernard</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Gollihar</surname> <given-names>J</given-names></string-name>, <string-name><surname>Musser</surname> <given-names>JM</given-names></string-name>. <year>2020</year>. <article-title>Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality</article-title>. <source>Am J Pathol</source> <volume>190</volume>:<fpage>2290</fpage>&#x2013;<lpage>2303</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Salazar</surname> <given-names>E</given-names></string-name>, <string-name><surname>Christensen</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Graviss</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Castillo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lopez</surname> <given-names>BV</given-names></string-name>, <string-name><surname>Eagar</surname> <given-names>TN</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>P</given-names></string-name>, <string-name><surname>Rogers</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shehabeldin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joseph</surname> <given-names>D</given-names></string-name>, <string-name><surname>Masud</surname> <given-names>F</given-names></string-name>, <string-name><surname>Leveque</surname> <given-names>C</given-names></string-name>, <string-name><surname>Olsen</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bernard</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Gollihar</surname> <given-names>J</given-names></string-name>, <string-name><surname>Musser</surname> <given-names>JM</given-names></string-name>. <year>2021</year>. <article-title>Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG</article-title>. <source>Am J Pathol</source> <volume>191</volume>:<fpage>90</fpage>&#x2013;<lpage>107</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="other"><string-name><surname>Rogers</surname> <given-names>R</given-names></string-name>, <string-name><surname>Shehadeh</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mylona</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Rich</surname> <given-names>J</given-names></string-name>, <string-name><surname>Neill</surname> <given-names>M</given-names></string-name>, <string-name><surname>Touzard-Romo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Geffert</surname> <given-names>S</given-names></string-name>, <string-name><surname>Larkin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bailey</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sweeney</surname> <given-names>J</given-names></string-name>, Mylonakis E. 2020. <article-title>Convalescent plasma for patients with severe COVID- 19: a matched cohort study</article-title>. <source>Clin Infect Dis</source> <fpage>ciaa1548</fpage>:Epub ahead of print.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Briggs</surname> <given-names>N</given-names></string-name>, <string-name><surname>Gormally</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Li</surname> <given-names>F</given-names></string-name>, <string-name><surname>Browning</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Treggiari</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Morrison</surname> <given-names>A</given-names></string-name>, <string-name><surname>Laurent-Rolle</surname> <given-names>M</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hendrickson</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Tormey</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Desruisseaux</surname> <given-names>MS</given-names></string-name>. <year>2021</year>. <article-title>Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19</article-title>. <source>PLoS One</source> <volume>16</volume>:<fpage>e0254453</fpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Shenoy</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Hettinger</surname> <given-names>AZ</given-names></string-name>, <string-name><surname>Fernandez</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Blumenthal</surname> <given-names>J</given-names></string-name>, <string-name><surname>Baez</surname> <given-names>V</given-names></string-name>. <year>2021</year>. <article-title>Early mortality benefit with COVID-19 convalescent plasma: a matched control study</article-title>. <source>Br J Haematol</source> doi:<pub-id pub-id-type="doi">10.1111/bjh.17272</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="other"><string-name><given-names>Arnold</given-names> <surname>Egloff SA</surname></string-name>, <string-name><surname>Junglen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Restivo</surname> <given-names>JSA</given-names></string-name>, <string-name><surname>Wongskhauluang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Doshi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schlauch</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fromell</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sears</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Correll</surname> <given-names>M</given-names></string-name>, <string-name><surname>Burris</surname> <given-names>HA</given-names></string-name>, <string-name><surname>LeMaistre</surname> <given-names>CF</given-names></string-name>. <year>2021</year>. <article-title>Association of Convalescent Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients Hospitalized with COVID-19 in the Community Setting</article-title>. doi:<pub-id pub-id-type="doi">10.1101/2021.06.02.21258190</pub-id>&#x0025;J medRxiv:2021.06.02.21258190.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Libster</surname> <given-names>R</given-names></string-name>, <string-name><surname>P&#x00E9;rez Marc</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wappner</surname> <given-names>D</given-names></string-name>, <string-name><surname>Coviello</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bianchi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Braem</surname> <given-names>V</given-names></string-name>, <string-name><surname>Esteban</surname> <given-names>I</given-names></string-name>, <string-name><surname>Caballero</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Wood</surname> <given-names>C</given-names></string-name>, <string-name><surname>Berrueta</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rondan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lescano</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cruz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ritou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Fern&#x00E1;ndez Vi&#x00F1;a</surname> <given-names>V</given-names></string-name>, <string-name><surname>&#x00C1;lvarez Paggi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Esperante</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ferreti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ofman</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ciganda</surname> <given-names>&#x00C1;</given-names></string-name>, <string-name><surname>Rodriguez</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lantos</surname> <given-names>J</given-names></string-name>, <string-name><surname>Valentini</surname> <given-names>R</given-names></string-name>, <string-name><surname>Itcovici</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hintze</surname> <given-names>A</given-names></string-name>, <string-name><surname>Oyarvide</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Etchegaray</surname> <given-names>C</given-names></string-name>, <string-name><surname>Neira</surname> <given-names>A</given-names></string-name>, <string-name><surname>Name</surname> <given-names>I</given-names></string-name>, <string-name><surname>Alfonso</surname> <given-names>J</given-names></string-name>, <string-name><surname>L&#x00F3;pez Castelo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Caruso</surname> <given-names>G</given-names></string-name>, <string-name><surname>Rapelius</surname> <given-names>S</given-names></string-name>, <string-name><surname>Alvez</surname> <given-names>F</given-names></string-name>, <string-name><surname>Etchenique</surname> <given-names>F</given-names></string-name>, <string-name><surname>Dimase</surname> <given-names>F</given-names></string-name>, <string-name><surname>Alvarez</surname> <given-names>D</given-names></string-name>, <string-name><surname>Aranda</surname> <given-names>SS</given-names></string-name>, <string-name><surname>S&#x00E1;nchez Yanotti</surname> <given-names>C</given-names></string-name>, <string-name><surname>De Luca</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jares Baglivo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Laudanno</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nowogrodzki</surname> <given-names>F</given-names></string-name>, <string-name><surname>Larrea</surname> <given-names>R</given-names></string-name>, <string-name><surname>Silveyra</surname> <given-names>M</given-names></string-name>, <string-name><surname>Leberzstein</surname> <given-names>G</given-names></string-name>, <string-name><surname>Debonis</surname> <given-names>A</given-names></string-name>, <string-name><surname>Molinos</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gonz&#x00E1;lez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Perez</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <year>2021</year>. <article-title>Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults</article-title>. <source>N Engl J Med</source> <volume>384</volume>:<fpage>610</fpage>&#x2013;<lpage>618</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Ray</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Paul</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Bandopadhyay</surname> <given-names>P</given-names></string-name>, <string-name><surname>D&#x2019;Rozario</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sarif</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lahiri</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bhowmik</surname> <given-names>D</given-names></string-name>, <string-name><surname>Vasudevan</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Maurya</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kanakan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>P</given-names></string-name>, <string-name><surname>Roy</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chaudhury</surname> <given-names>K</given-names></string-name>, <string-name><surname>Maiti</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bagchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maiti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Perwez</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Mondal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tewari</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mandal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Roy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Saha</surname> <given-names>M</given-names></string-name>, <string-name><surname>Biswas</surname> <given-names>D</given-names></string-name>, <string-name><surname>Maiti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chakraborty</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sarkar</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Haldar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Saha</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sengupta</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pandey</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bhattacharya</surname> <given-names>P</given-names></string-name>, <string-name><surname>Paul</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ganguly</surname> <given-names>D</given-names></string-name>. <year>2020</year>. <article-title>Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial</article-title>. <source>medRxiv</source> doi:<pub-id pub-id-type="doi">10.1101/2020.11.25.20237883</pub-id> &#x0025;J medRxiv:2020.11.25.20237883.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Avendano-Sola</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ramos-Martinez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Munez-Rubio</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ruiz-Antoran</surname> <given-names>B</given-names></string-name>, <string-name><given-names>Malo</given-names> <surname>de Molina R</surname></string-name>, <string-name><surname>Torres</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fernandez-Cruz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Callejas-Diaz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Calderon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Payares-Herrera</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salcedo</surname> <given-names>I</given-names></string-name>, <string-name><surname>Romera</surname> <given-names>I</given-names></string-name>, <string-name><surname>Lora-Tamayo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mancheno-Losa</surname> <given-names>M</given-names></string-name>, <string-name><surname>Paciello</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Villegas</surname> <given-names>C</given-names></string-name>, <string-name><surname>Estrada</surname> <given-names>V</given-names></string-name>, <string-name><surname>Saez-Serrano</surname> <given-names>I</given-names></string-name>, <string-name><surname>Porras-Leal</surname> <given-names>ML</given-names></string-name>, <string-name><given-names>Jarilla-Fernandez</given-names> <surname>MdC</surname></string-name>, <string-name><surname>Pano-Pardo</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Moreno-Chulilla</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Arrieta-Aldea</surname> <given-names>I</given-names></string-name>, <string-name><surname>Bosch</surname> <given-names>A</given-names></string-name>, <string-name><surname>Belhassen-Garcia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lopez-Villar</surname> <given-names>O</given-names></string-name>, <string-name><surname>Ramos-Garrido</surname> <given-names>A</given-names></string-name>, <string-name><surname>Blanco</surname> <given-names>L</given-names></string-name>, <string-name><surname>Madrigal</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Contreras</surname> <given-names>E</given-names></string-name>, <string-name><surname>Muniz-Diaz</surname> <given-names>E</given-names></string-name>, <string-name><surname>Domingo-Morera</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Casas-Flecha</surname> <given-names>I</given-names></string-name>, <string-name><surname>Perez-Olmeda</surname> <given-names>M</given-names></string-name>, <string-name><surname>Garcia- Perez</surname> <given-names>J</given-names></string-name>, <string-name><surname>Alcami</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bueno</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Duarte</surname> <given-names>RF</given-names></string-name>. <year>2021</year>. <article-title>A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia</article-title>. <source>J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1172/JCI152740:152740</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Janiaud</surname> <given-names>P</given-names></string-name>, <string-name><surname>Axfors</surname> <given-names>C</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Gloy</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ebrahimi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hepprich</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Haber</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Khanna</surname> <given-names>N</given-names></string-name>, <string-name><surname>Moher</surname> <given-names>D</given-names></string-name>, <string-name><surname>Goodman</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Ioannidis</surname> <given-names>JPA</given-names></string-name>, <string-name><surname>Hemkens</surname> <given-names>LG</given-names></string-name>. <year>2021</year>. <article-title>Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis</article-title>. <source>JAMA</source> <volume>325</volume>:<fpage>1185</fpage>&#x2013;<lpage>1195</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Hamilton</surname> <given-names>FW</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Lilford</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Hemming</surname> <given-names>K</given-names></string-name>. <year>2021</year>. <article-title>Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial</article-title>. <source>Int J Infect Dis S</source><fpage>1201</fpage>&#x2013;<lpage>9712</lpage>:00523-3.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Shoham</surname> <given-names>S</given-names></string-name>, <string-name><surname>Grossman</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Musser</surname> <given-names>J</given-names></string-name>, <string-name><surname>Salazar</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hartman</surname> <given-names>WR</given-names></string-name>, <string-name><surname>Bouvier</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>STH</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis</article-title>. <source>Mayo Clin Proc</source> <volume>96</volume>:<fpage>1262</fpage>&#x2013;<lpage>1275</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Piechotta</surname> <given-names>V</given-names></string-name>, <string-name><surname>Iannizzi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chai</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Valk</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kimber</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dorando</surname> <given-names>E</given-names></string-name>, <string-name><surname>Monsef</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wood</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Lamikanra</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>McQuilten</surname> <given-names>Z</given-names></string-name>, <string-name><surname>So-Osman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Estcourt</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Skoetz</surname> <given-names>N</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review</article-title>. <source>Cochrane Database Syst Rev</source> <volume>5</volume>:Cd013600.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Cruciani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bongiovanni</surname> <given-names>G</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality</article-title>. <source>Transfusion</source> <volume>61</volume>:<fpage>1988</fpage>&#x2013;<lpage>1990</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Senese</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Shoham</surname> <given-names>S</given-names></string-name>, <string-name><surname>Grossman</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ.</given-names></string-name> <year>2021</year>. <article-title>Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence</article-title>. <source>Front Med (Lausanne</source>) <volume>8</volume>:<fpage>684151</fpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="website"><string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Grossman</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Shoham</surname> <given-names>S</given-names></string-name>. <year>2021</year>. <article-title>Please Reevaluate the Data on Convalescent Plasma for COVID-19</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl_mpt_DHE_2021-08-30&#x0026;eun=g1783322d0r&#x0026;utm_source=Sailthru&#x0026;utm_medium=email&#x0026;utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-08-30&#x0026;utm_term=NL_Daily_DHE_dual-gmail-definition">https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl_mpt_DHE_2021-08-30&#x0026;eun=g1783322d0r&#x0026;utm_source=Sailthru&#x0026;utm_medium=email&#x0026;utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-08-30&#x0026;utm_term=NL_Daily_DHE_dual-gmail-definition</ext-link>. Accessed <date-in-citation content-type="access-date">August 31, 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>de Candia</surname> <given-names>P</given-names></string-name>, <string-name><surname>Prattichizzo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Garavelli</surname> <given-names>S</given-names></string-name>, <string-name><surname>La Grotta</surname> <given-names>R</given-names></string-name>, <string-name><surname>De Rosa</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pontarelli</surname> <given-names>A</given-names></string-name>, <string-name><surname>Parrella</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ceriello</surname> <given-names>A</given-names></string-name>, <string-name><surname>Matarese</surname> <given-names>G.</given-names></string-name> <year>2021</year>. <article-title>Effect of time and titer in convalescent plasma therapy for COVID-19</article-title>. <source>iScience</source> doi:<pub-id pub-id-type="doi">10.1016/j.isci.2021.102898:102898</pub-id>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Kloypan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Saesong</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sangsuemoon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chantharit</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mongkhon</surname> <given-names>P</given-names></string-name>. <year>2021</year>. <article-title>Convalescent Plasma for COVID-19: A Meta-analysis of Clinical Trials and Real-World Evidence</article-title>. <source>Eur J Clin Invest</source> doi:<pub-id pub-id-type="doi">10.1111/eci.13663:e13663</pub-id>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="other"><string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Corsini</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cruciani</surname> <given-names>M</given-names></string-name>. 2021. <article-title>Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews</article-title>. <source>Diagnostics</source>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="website">62. <collab>Anonymous</collab>. <year>2021</year>. <source>Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients</source>. <ext-link ext-link-type="uri" xlink:href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-monitoring-pooled-international-trials-convalescent-plasma-covid19-hospitalized-patients">https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-monitoring-pooled-international-trials-convalescent-plasma-covid19-hospitalized-patients</ext-link>. Accessed <date-in-citation content-type="access-date">August 31, 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>L</given-names></string-name>-a, <string-name><surname>Burnouf</surname> <given-names>T</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>. <year>2021</year>. <article-title>COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors</article-title>. <source>Viruses</source> <volume>13</volume>:<fpage>1594</fpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cruciani</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>How Safe Is COVID-19 Convalescent Plasma?</article-title> <source>Mayo Clin Proc</source> <volume>96</volume>:<fpage>2279</fpage>&#x2013;<lpage>2281</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Kunze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Lesser</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Klompas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Hodge</surname> <given-names>DO</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Rea</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Whelan</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Clayburn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Spiegel</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Ripoll</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Andersen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Buras</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Herasevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Regimbal</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Blair</surname> <given-names>JE</given-names></string-name>, <string-name><surname>van buskirk</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Winters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>JR</given-names></string-name>, <string-name><surname>van Helmond</surname> <given-names>N</given-names></string-name>, <string-name><surname>Butterfield</surname> <given-names>BP</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>M</given-names></string-name>, <string-name><surname>Diaz Soto</surname> <given-names>J</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Verdun</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>P</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>D</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>. <year>2020</year>. <article-title>Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients</article-title>. <source>Mayo Clinic Proceedings</source> <volume>95</volume>:<fpage>1888</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Wheatley</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Kent</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>DeKosky</surname> <given-names>BJ</given-names></string-name>. <year>2020</year>. <article-title>Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies</article-title>. <source>Nature Microbiology</source> <volume>5</volume>:<fpage>1185</fpage>&#x2013;<lpage>1191</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations</article-title>. <source>Expert Rev Vaccines</source> doi:<pub-id pub-id-type="doi">10.1080/14760584.2021.1932475:1-8</pub-id>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Vickers</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Sariol</surname> <given-names>A</given-names></string-name>, <string-name><surname>Leon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ehlers</surname> <given-names>A</given-names></string-name>, <string-name><surname>Locher</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Dubay</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>L</given-names></string-name>, <string-name><surname>Voss</surname> <given-names>D</given-names></string-name>, <string-name><surname>Odle</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Holida</surname> <given-names>M</given-names></string-name>, <string-name><surname>Merrill</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Perlman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Knudson</surname> <given-names>CM</given-names></string-name>. <year>2021</year>. <article-title>Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors</article-title>. <source>Transfusion</source> doi:<pub-id pub-id-type="doi">10.1111/trf.16401</pub-id>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="website">69. <collab>Anonymous</collab>. <year>2021</year>. <source>CoVIg-19 Plasma Alliance Announces Topline Results from NIH- Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine</source>. <ext-link ext-link-type="uri" xlink:href="https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/">https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/</ext-link>. Accessed <date-in-citation content-type="access-date">April 2, 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><collab>Anonymous</collab>. <year>2020</year>. <article-title>ACTIV-3/TICO LY-CoV555 Study Group. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19</article-title>. <source>N Engl J Med</source> <volume>384</volume>:<fpage>905</fpage>&#x2013;<lpage>914</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Dougan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nirula</surname> <given-names>A</given-names></string-name>, <string-name><surname>Azizad</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mocherla</surname> <given-names>B</given-names></string-name>, <string-name><surname>Gottlieb</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hebert</surname> <given-names>C</given-names></string-name>, <string-name><surname>Perry</surname> <given-names>R</given-names></string-name>, <string-name><surname>Boscia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Heller</surname> <given-names>B</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>J</given-names></string-name>, <string-name><surname>Crystal</surname> <given-names>C</given-names></string-name>, <string-name><surname>Igbinadolor</surname> <given-names>A</given-names></string-name>, <string-name><surname>Huhn</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cardona</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shawa</surname> <given-names>I</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>P</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Van Naarden</surname> <given-names>J</given-names></string-name>, <string-name><surname>Custer</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Durante</surname> <given-names>M</given-names></string-name>, <string-name><surname>Oakley</surname> <given-names>G</given-names></string-name>, <string-name><surname>Schade</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Holzer</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Ebert</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Higgs</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Kallewaard</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Sabo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Dabora</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Klekotka</surname> <given-names>P</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Skovronsky</surname> <given-names>DM</given-names></string-name>. <year>2021</year>. <article-title>Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19</article-title>. <source>NEJM</source> doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2102685</pub-id>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dragotakes</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>N</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>R</given-names></string-name>. <year>2021</year>. <article-title>Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives?</article-title> <source>Elife</source> <volume>4</volume>:<fpage>e69866</fpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>COVID-19 convalescent plasma therapy: hit fast, hit hard!</article-title> . <source>Vox Sang</source>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Franchini</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review</article-title>. <source>Transfus Apher Sci</source> doi:<pub-id pub-id-type="doi">10.1016/j.transci.2021.103071:103071</pub-id>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Klassen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Ford</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Senese</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Wiggins</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Bostrom</surname> <given-names>BC</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Nicholson</surname> <given-names>WT</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Hartman</surname> <given-names>WR</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Fairweather</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Paneth</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>. <year>2021</year>. <article-title>Use of convalescent plasma in COVID-19 patients with immunosuppression</article-title>. <source>Transfusion</source> <volume>61</volume>:<fpage>2503</fpage>&#x2013;<lpage>2511</lpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Thompson</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Rubinstein</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Choueiri</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Flora</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Gulati</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Hwang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Koshkin</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Papadopoulos</surname> <given-names>EB</given-names></string-name>, <string-name><surname>Robilotti</surname> <given-names>EV</given-names></string-name>, <string-name><surname>Su</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Wulff- Burchfield</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>PP</given-names></string-name>, <string-name><surname>Mishra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Senefeld</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Warner</surname> <given-names>JL</given-names></string-name>. <year>2021</year>. <article-title>Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19</article-title>. <source>JAMA Oncol</source> doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2021.1799</pub-id>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Casadevall</surname> <given-names>A</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Joyner</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>L-a</given-names></string-name>. <year>2021</year>. <article-title>SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities</article-title>. <source>The Journal of Clinical Investigation</source> doi:<pub-id pub-id-type="doi">10.1172/JCI148832</pub-id>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Moscato</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mazzetti</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lucenteforte</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rosellini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cara</surname> <given-names>A</given-names></string-name>, <string-name><surname>Quaranta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mainardi</surname> <given-names>V</given-names></string-name>, <string-name><surname>Villa</surname> <given-names>P</given-names></string-name>, <string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lanza</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bianco</surname> <given-names>I</given-names></string-name>, <string-name><surname>Mazzoni</surname> <given-names>A</given-names></string-name>, <string-name><surname>Falcone</surname> <given-names>M</given-names></string-name>, <string-name><surname>Menichetti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Maggi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Freer</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pistello</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody</article-title>. <source>Journal of Clinical Virology Plus</source> <volume>1</volume>:<fpage>100016</fpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Jahrsd&#x00F6;rfer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Kroschel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ludwig</surname> <given-names>C</given-names></string-name>, <string-name><surname>Corman</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Schwarz</surname> <given-names>T</given-names></string-name>, <string-name><surname>K&#x00F6;rper</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rojewski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lotfi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Weinstock</surname> <given-names>C</given-names></string-name>, <string-name><surname>Drosten</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seifried</surname> <given-names>E</given-names></string-name>, <string-name><surname>Stamminger</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gro&#x00DF;</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Schrezenmeier</surname> <given-names>H</given-names></string-name>. <year>2021</year>. <article-title>Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS- CoV-2 Antibody Testing</article-title>. <source>J Infect Dis</source> <volume>223</volume>:<fpage>796</fpage>&#x2013;<lpage>801</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Di Germanio</surname> <given-names>C</given-names></string-name>, <string-name><surname>Simmons</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kelly</surname> <given-names>K</given-names></string-name>, <string-name><surname>Martinelli</surname> <given-names>R</given-names></string-name>, <string-name><surname>Darst</surname> <given-names>O</given-names></string-name>, <string-name><surname>Azimpouran</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hazegh</surname> <given-names>K</given-names></string-name>, <string-name><surname>Grebe</surname> <given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>P</given-names></string-name>, <string-name><surname>Orzechowski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gomez</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Livny</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hung</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Vassallo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Busch</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>LJ.</given-names></string-name> <year>2021</year>. <article-title>SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance</article-title>. <source>Transfusion</source> doi:<pub-id pub-id-type="doi">10.1111/trf.16555:2021.03.24.21254260</pub-id>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Misset</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hoste</surname> <given-names>E</given-names></string-name>, <string-name><surname>Donneau</surname> <given-names>A-F</given-names></string-name>, <string-name><surname>Grimaldi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Meyfroidt</surname> <given-names>G</given-names></string-name>, <string-name><surname>Moutschen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Compernolle</surname> <given-names>V</given-names></string-name>, <string-name><surname>Gothot</surname> <given-names>A</given-names></string-name>, <string-name><surname>Desmecht</surname> <given-names>D</given-names></string-name>, <string-name><surname>Garigliany</surname> <given-names>M</given-names></string-name>, <string-name><surname>Najdovski</surname> <given-names>T</given-names></string-name>, <string-name><surname>Laterre</surname> <given-names>P-F</given-names></string-name>. <year>2020</year>. <article-title>A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol</article-title>. <source>BMC Pulmonary Medicine</source> <volume>20</volume>:<fpage>317</fpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Mari&#x00EB;n</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ceulemans</surname> <given-names>A</given-names></string-name>, <string-name><surname>Michiels</surname> <given-names>J</given-names></string-name>, <string-name><surname>Heyndrickx</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kerkhof</surname> <given-names>K</given-names></string-name>, <string-name><surname>Foque</surname> <given-names>N</given-names></string-name>, <string-name><surname>Widdowson</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Mortgat</surname> <given-names>L</given-names></string-name>, <string-name><surname>Duysburgh</surname> <given-names>E</given-names></string-name>, <string-name><surname>Desombere</surname> <given-names>I</given-names></string-name>, <string-name><surname>Jansens</surname> <given-names>H</given-names></string-name>, <string-name><surname>Van Esbroeck</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ari&#x00EB;n</surname> <given-names>KK.</given-names></string-name> <year>2021</year>. <article-title>Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay</article-title>. <source>J Virol Methods</source> <volume>288</volume>:<fpage>114025</fpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Betrains</surname> <given-names>A</given-names></string-name>, <string-name><surname>Godinas</surname> <given-names>L</given-names></string-name>, <string-name><surname>Woei</surname> <given-names>AJF</given-names></string-name>, <string-name><surname>Rosseels</surname> <given-names>W</given-names></string-name>, <string-name><surname>Van Herck</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lorent</surname> <given-names>N</given-names></string-name>, <string-name><surname>Dierickx</surname> <given-names>D</given-names></string-name>, <string-name><surname>Compernolle</surname> <given-names>V</given-names></string-name>, <string-name><surname>Meyfroidt</surname> <given-names>G</given-names></string-name>, <string-name><surname>Vanderbeke</surname> <given-names>L</given-names></string-name>, <string-name><surname>Vergote</surname> <given-names>V</given-names></string-name>, <string-name><surname>Lagrou</surname> <given-names>K</given-names></string-name>, <string-name><surname>Verhamme</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wauters</surname> <given-names>J</given-names></string-name>, <string-name><surname>Vermeersch</surname> <given-names>P</given-names></string-name>, <string-name><surname>Devos</surname> <given-names>T</given-names></string-name>, <string-name><surname>Maes</surname> <given-names>P</given-names></string-name>, <string-name><surname>Vanderschueren</surname> <given-names>S.</given-names></string-name> <year>2021</year>. <article-title>Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies</article-title>. <source>Br J Haematol</source> <volume>192</volume>:<fpage>1100</fpage>&#x2013;<lpage>1105</lpage>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Okba</surname> <given-names>NMA</given-names></string-name>, <string-name><surname>M&#x00FC;ller</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Li</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>C</given-names></string-name>, <string-name><surname>GeurtsvanKessel</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Corman</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Lamers</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Sikkema</surname> <given-names>RS</given-names></string-name>, <string-name><surname>de Bruin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chandler</surname> <given-names>FD</given-names></string-name>, <string-name><surname>Yazdanpanah</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Le Hingrat</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Descamps</surname> <given-names>D</given-names></string-name>, <string-name><surname>Houhou- Fidouh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Reusken</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bosch</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Drosten</surname> <given-names>C</given-names></string-name>, <string-name><surname>Koopmans</surname> <given-names>MPG</given-names></string-name>, <string-name><surname>Haagmans</surname> <given-names>BL.</given-names></string-name> <year>2020</year>. <article-title>Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients</article-title>. <source>Emerg Infect Dis</source> <volume>26</volume>:<fpage>1478</fpage>&#x2013;<lpage>1488</lpage>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal">85. <string-name><surname>Amanat</surname> <given-names>F</given-names></string-name>, <string-name><surname>White</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Miorin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Strohmeier</surname> <given-names>S</given-names></string-name>, <string-name><surname>McMahon</surname> <given-names>M</given-names></string-name>, <string-name><surname>Meade</surname> <given-names>P</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W-C</given-names></string-name>, <string-name><surname>Albrecht</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Simon</surname> <given-names>V</given-names></string-name>, <string-name><surname>Martinez-Sobrido</surname> <given-names>L</given-names></string-name>, <string-name><surname>Moran</surname> <given-names>T</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-Sastre</surname> <given-names>A</given-names></string-name>, <string-name><surname>Krammer</surname> <given-names>F.</given-names></string-name> <year>2020</year>. <source>An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening</source>. <volume>58</volume>:<fpage>e108</fpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Oguntuyo</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Hung</surname> <given-names>C-T</given-names></string-name>, <string-name><surname>Ikegame</surname> <given-names>S</given-names></string-name>, <string-name><surname>Acklin</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Kowdle</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Carmichael</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Chiu</surname> <given-names>H- p</given-names></string-name>, <string-name><surname>Azarm</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Amanat</surname> <given-names>F</given-names></string-name>, <string-name><surname>Klingler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Baine</surname> <given-names>I</given-names></string-name>, <string-name><surname>Arinsburg</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bandres</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Siddiquey</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Schilke</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Woolard</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Duty</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Kraus</surname> <given-names>TA</given-names></string-name>, <string-name><surname>Moran</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Tortorella</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Gamarnik</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Hioe</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Zolla-Pazner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ivanov</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Kamil</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Krammer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>B</given-names></string-name>. <year>2020</year>. <article-title>Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera</article-title>. <source>mBio</source> <volume>12</volume>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><collab>Anonymous</collab>. <string-name><surname>Wu</surname>, <given-names>Fan</given-names></string-name> and <string-name><surname>Wang</surname>, <given-names>Aojie</given-names></string-name> and <string-name><surname>Liu</surname>, <given-names>Mei</given-names></string-name> and <string-name><surname>Wang</surname>, <given-names>Qimin</given-names></string-name> and <string-name><surname>Chen</surname>, <given-names>Jun</given-names></string-name> and <string-name><surname>Xia</surname>, <given-names>Shuai</given-names></string-name> and <string-name><surname>Ling</surname>, <given-names>Yun</given-names></string-name> and <string-name><surname>Zhang</surname>, <given-names>Yuling</given-names></string-name> and <string-name><surname>Xun</surname>, <given-names>Jingna</given-names></string-name> and <string-name><surname>Lu</surname>, <given-names>Lu</given-names></string-name> and <string-name><surname>Jiang</surname>, <given-names>Shibo</given-names></string-name> and <string-name><surname>Lu</surname>, <given-names>Hongzhou</given-names></string-name> and <string-name><surname>Wen</surname>, <given-names>Yumei</given-names></string-name> and <string-name><surname>Huang</surname>, <given-names>Jinghe</given-names></string-name>, <source>Neutralizing Antibody Responses to SARS- CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications (3/28/2020)</source>. Available at SSRN: <ext-link ext-link-type="uri" xlink:href="https://ssrn.com/abstract=3566211">https://ssrn.com/abstract=3566211</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2139/ssrn.3566211">http://dx.doi.org/10.2139/ssrn.3566211</ext-link>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal">88. <string-name><surname>Beltr&#x00E1;n-Pavez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Riquelme-Barrios</surname> <given-names>S</given-names></string-name>, <string-name><surname>Oyarz&#x00FA;n-Arrau</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gaete-Argel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gonz&#x00E1;lez-Stegmaier</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cereceda-Solis</surname> <given-names>K</given-names></string-name>, <string-name><surname>Aguirre</surname> <given-names>A</given-names></string-name>, <string-name><surname>Travisany</surname> <given-names>D</given-names></string-name>, <string-name><surname>Palma-Vejares</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barriga</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Gaggero</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mart&#x00ED;nez- Valdebenito</surname> <given-names>C</given-names></string-name>, <string-name><surname>Corre</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Ferr&#x00E9;s</surname> <given-names>M</given-names></string-name>, <string-name><surname>Balcells</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Fernandez</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ram&#x00ED;rez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Villarroel</surname> <given-names>F</given-names></string-name>, <string-name><surname>Valiente- Echeverr&#x00ED;a</surname> <given-names>F</given-names></string-name>, <string-name><surname>Soto-Rifo</surname> <given-names>R</given-names></string-name>. <year>2021</year>. <source>Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile</source>. <volume>7</volume>:<fpage>eabe6855</fpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Bennett-Guerrero</surname> <given-names>E</given-names></string-name>, <string-name><surname>Romeiser</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Talbot</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Ahmed</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mamone</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Hearing</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Salman</surname> <given-names>H</given-names></string-name>, <string-name><surname>Holiprosad</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Freedenberg</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Browne</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Cosgrove</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Shevik</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Generale</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Andrew</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Nachman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fries</surname> <given-names>BC</given-names></string-name>. <year>2021</year>. <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial</article-title>. <source>Crit Care Med</source> doi:<pub-id pub-id-type="doi">10.1097/ccm.0000000000005066</pub-id>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="other"><string-name><surname>Holm</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lundgren</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kjedlsen-Kragh</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ljungquist</surname> <given-names>O</given-names></string-name>, <string-name><surname>Bottiger</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wiken</surname> <given-names>C</given-names></string-name>, <string-name><surname>Oberg</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fernstrom</surname> <given-names>N</given-names></string-name>, <string-name><surname>Rosendal</surname> <given-names>E</given-names></string-name>, <string-name><surname>Overby</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bystrom</surname> <given-names>J</given-names></string-name>, <string-name><surname>Forsell</surname> <given-names>M</given-names></string-name>, <string-name><surname>Landin-Olsson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rasmussen</surname> <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma treatment of COVID-19: Results from a prematurely terminated randomized controlled open-label study in Southern Sweden</article-title>. <source>BMC Research Note</source>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><string-name><surname>Rasheed</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Fatak</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Hashim</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Maulood</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Kabah</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Almusawi</surname> <given-names>YA</given-names></string-name>, <string-name><surname>Abdulamir</surname> <given-names>AS</given-names></string-name>. <year>2020</year>. <article-title>The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq</article-title>. <source>Infez Med</source> <volume>28</volume>:<fpage>357</fpage>&#x2013;<lpage>366</lpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><string-name><surname>Balcells</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Rojas</surname> <given-names>L</given-names></string-name>, <string-name><surname>Le Corre</surname> <given-names>N</given-names></string-name>, <string-name><surname>Mart&#x00ED;nez-Valdebenito</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ceballos</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Ferr&#x00E9;s</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vizcaya</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mondaca</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huete</surname> <given-names>&#x00C1;</given-names></string-name>, <string-name><surname>Castro</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sarmiento</surname> <given-names>M</given-names></string-name>, <string-name><surname>Villarroel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Pizarro</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>P</given-names></string-name>, <string-name><surname>Santander</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lara</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ferrada</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vargas-Salas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Beltr&#x00E1;n-Pavez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Soto-Rifo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Valiente- Echeverr&#x00ED;a</surname> <given-names>F</given-names></string-name>, <string-name><surname>Caglevic</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mahave</surname> <given-names>M</given-names></string-name>, <string-name><surname>Selman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gazit&#x00FA;a</surname> <given-names>R</given-names></string-name>, <string-name><surname>Briones</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Villarroel-Espindola</surname> <given-names>F</given-names></string-name>, <string-name><surname>Balmaceda</surname> <given-names>C</given-names></string-name>, <string-name><surname>Espinoza</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Pereira</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nervi</surname> <given-names>B</given-names></string-name>. <year>2020</year>. <article-title>Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial</article-title>. <source>PLoS Medicine</source> doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1003415</pub-id>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>AlQahtani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Abdulrahman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Almadani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Alali</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Al Zamrooni</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Hejab</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Conroy</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Wasif</surname> <given-names>P</given-names></string-name>, <string-name><surname>Atkin</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Otoom</surname> <given-names>S</given-names></string-name>, <string-name><surname>Abduljalil</surname> <given-names>M.</given-names></string-name> <year>2020</year>. <article-title>Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease</article-title>. <source>Sci Rep</source> <volume>11</volume>:<fpage>9927</fpage>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Bajpai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maheshwari</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chhabra</surname> <given-names>K</given-names></string-name>, <string-name><surname>kale</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>A</given-names></string-name>, <string-name><surname>Narayanan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>E</given-names></string-name>, <string-name><surname>Trehanpati</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bihari</surname> <given-names>C</given-names></string-name>, <string-name><surname>Agarwal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>K</given-names></string-name>, <string-name><given-names>Gupta</given-names> <surname>Uk</surname></string-name>, <string-name><surname>Bhardwaj</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>G</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>M</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>R</given-names></string-name>, <string-name><surname>Yadav</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maiwall</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sarin</surname> <given-names>SK</given-names></string-name>. <year>2020</year>. <article-title>Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial</article-title>. <source>medRxiv</source> doi:<pub-id pub-id-type="doi">10.1101/2020.10.25.20219337</pub-id> &#x0025;J medRxiv:2020.10.25.20219337.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>B&#x00E9;gin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Callum</surname> <given-names>J</given-names></string-name>, <string-name><surname>Heddle</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Cook</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zeller</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Tinmouth</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fergusson</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Cushing</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Glesby</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Chass&#x00E9;</surname> <given-names>M</given-names></string-name>, <string-name><surname>Devine</surname> <given-names>DV</given-names></string-name>, <string-name><surname>Robitalle</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bazin</surname> <given-names>R</given-names></string-name>, <string-name><surname>Shehata</surname> <given-names>N</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>McGeer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Scales</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Turgeon</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Zarychanski</surname> <given-names>R</given-names></string-name>, <string-name><surname>Daneman</surname> <given-names>N</given-names></string-name>, <string-name><surname>Carl</surname> <given-names>R</given-names></string-name>, <string-name><surname>Amorim</surname> <given-names>L</given-names></string-name>, <string-name><surname>Gabe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ellis</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sachais</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Loftsgard</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Jamula</surname> <given-names>E</given-names></string-name>, <string-name><surname>Carruthers</surname> <given-names>J</given-names></string-name>, <string-name><surname>Duncan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lucier</surname> <given-names>K</given-names></string-name>, <string-name><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Armali</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kron</surname> <given-names>A</given-names></string-name>, <string-name><surname>Modi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Auclair</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Cerro</surname> <given-names>S</given-names></string-name>, <string-name><surname>Avram</surname> <given-names>M</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>DM</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial</article-title>. <source>Trials</source> <volume>22</volume>:<fpage>323</fpage>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>B&#x00E9;gin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Callum</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jamula</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Cook</surname> <given-names>R</given-names></string-name>, <string-name><surname>Heddle</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Tinmouth</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zeller</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Beaudoin-Bussi&#x00E8;re</surname> <given-names>G</given-names></string-name>, <string-name><surname>Amorim</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bazin</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cadogan Lofstgard</surname> <given-names>K</given-names></string-name>, <string-name><surname>Carl</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chass&#x00E9;</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cushing</surname> <given-names>M</given-names></string-name>, <string-name><surname>Daneman</surname> <given-names>N</given-names></string-name>, <string-name><surname>Devine</surname> <given-names>DV</given-names></string-name>, <string-name><surname>Dumaresq</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ferguson</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gabe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Glesby</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>McGeer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Robitaille</surname> <given-names>N</given-names></string-name>, <string-name><surname>Sachais</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Scales</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Shehata</surname> <given-names>N</given-names></string-name>, <string-name><surname>Turgeon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wood</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zarychanski</surname> <given-names>R</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>DM</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial</article-title>. <source>medrXiv [Preprint]</source> doi:<pub-id pub-id-type="doi">10.1101/2021.06.29.21259427</pub-id> &#x0025;J medRxiv:2021.06.29.21259427.</mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><string-name><surname>Angus</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Berry</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lewis</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Al-Beidh</surname> <given-names>F</given-names></string-name>, <string-name><surname>Arabi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>van Bentum-Puijk</surname> <given-names>W</given-names></string-name>, <string-name><surname>Bhimani</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bonten</surname> <given-names>M</given-names></string-name>, <string-name><surname>Broglio</surname> <given-names>K</given-names></string-name>, <string-name><surname>Brunkhorst</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Chiche</surname> <given-names>JD</given-names></string-name>, <string-name><surname>De Jong</surname> <given-names>M</given-names></string-name>, <string-name><surname>Detry</surname> <given-names>M</given-names></string-name>, <string-name><surname>Goossens</surname> <given-names>H</given-names></string-name>, <string-name><surname>Gordon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Green</surname> <given-names>C</given-names></string-name>, <string-name><surname>Higgins</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Hullegie</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kruger</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lamontagne</surname> <given-names>F</given-names></string-name>, <string-name><surname>Litton</surname> <given-names>E</given-names></string-name>, <string-name><surname>Marshall</surname> <given-names>J</given-names></string-name>, <string-name><surname>McGlothlin</surname> <given-names>A</given-names></string-name>, <string-name><surname>McGuinness</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mouncey</surname> <given-names>P</given-names></string-name>, <string-name><surname>Murthy</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nichol</surname> <given-names>A</given-names></string-name>, <string-name><surname>O&#x2019;Neill</surname> <given-names>GK</given-names></string-name>, <string-name><surname>Parke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Parker</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rohde</surname> <given-names>G</given-names></string-name>, <string-name><surname>Rowan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>A</given-names></string-name>, <string-name><surname>Young</surname> <given-names>P</given-names></string-name>, <string-name><surname>Derde</surname> <given-names>L</given-names></string-name>, <string-name><surname>McArthur</surname> <given-names>C</given-names></string-name>, <string-name><surname>Webb</surname> <given-names>SA</given-names></string-name>. <year>2020</year>. <article-title>The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design</article-title>. <source>Ann Am Thorac Soc</source> <volume>17</volume>:<fpage>879</fpage>&#x2013;<lpage>891</lpage>.</mixed-citation></ref>
<ref id="c98"><label>98.</label><mixed-citation publication-type="journal"><string-name><surname>Estcourt</surname> <given-names>LJ</given-names></string-name>. <year>2021</year>. <article-title>Convalescent Plasma in Critically ill Patients with COVID-19</article-title>. <source>medrXiv [Preprint</source>] doi:<pub-id pub-id-type="doi">10.1101/2021.06.11.21258760</pub-id> &#x0025;J medRxiv:2021.06.11.21258760.</mixed-citation></ref>
<ref id="c99"><label>99.</label><mixed-citation publication-type="website">99. <collab>Anonymous</collab>. <source>National COVID19 Convalescent Plasma Project. Commentary from the COVID- 19 Convalescent Plasma Project (CCPP19) Leadership Group on &#x0022;Early Convalescent Plasma for High-Risk Outpatients with Covid-19&#x0022;</source>. Accessed online at <ext-link ext-link-type="uri" xlink:href="https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-23.docx">https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-23.docx</ext-link> on August 25, <year>2021</year>.</mixed-citation></ref>
<ref id="c100"><label>100.</label><mixed-citation publication-type="website">100. <collab>Anonymous</collab>. March 2, <year>2021</year>. <source>NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms</source>. <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms">https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms</ext-link>. Accessed</mixed-citation></ref>
<ref id="c101"><label>101.</label><mixed-citation publication-type="journal"><string-name><given-names>Beltran</given-names> <surname>Gonzalez JL</surname></string-name>, <string-name><given-names>Gonzalez</given-names> <surname>Gamez M</surname></string-name>, <string-name><given-names>Mendoza</given-names> <surname>Enciso EA</surname></string-name>, <string-name><given-names>Esparza</given-names> <surname>Maldonado RJ</surname></string-name>, <string-name><given-names>Hernandez</given-names> <surname>Palacios D</surname></string-name>, <string-name><given-names>Duenas</given-names> <surname>Campos S</surname></string-name>, <string-name><given-names>Ovalle</given-names> <surname>Robles I</surname></string-name>, <string-name><given-names>Macias</given-names> <surname>Guzman MJ</surname></string-name>, <string-name><given-names>Garcia</given-names> <surname>Diaz AL</surname></string-name>, <string-name><given-names>Gutierrez</given-names> <surname>Pena CM</surname></string-name>, <string-name><given-names>Reza</given-names> <surname>Escalera AL</surname></string-name>, <string-name><given-names>Tiscareno</given-names> <surname>Gutierrez MT</surname></string-name>, <string-name><given-names>Galvan</given-names> <surname>Guerra E</surname></string-name>, <string-name><given-names>Dorantes Morales</given-names> <surname>MdR</surname></string-name>, <string-name><given-names>Martinez</given-names> <surname>Medina L</surname></string-name>, <string-name><given-names>Monroy</given-names> <surname>Colin VA</surname></string-name>, <string-name><given-names>Arreola</given-names> <surname>Guerra JM</surname></string-name>. <year>2021</year>. <article-title>Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients</article-title>. <source>A controlled clinical trial. medrXiv [Preprint</source>] doi:<pub-id pub-id-type="doi">10.1101/2021.03.28.21254507</pub-id> &#x0025;J medRxiv:2021.03.28.21254507.</mixed-citation></ref>
<ref id="c102"><label>102.</label><mixed-citation publication-type="journal"><string-name><surname>Sekine</surname> <given-names>L</given-names></string-name>, <string-name><surname>Arns</surname> <given-names>B</given-names></string-name>, <string-name><surname>Fabro</surname> <given-names>BR</given-names></string-name>, <string-name><surname>Cipolatt</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Machado</surname> <given-names>RRG</given-names></string-name>, <string-name><surname>Durigon</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Parolo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pellegrini</surname> <given-names>JAS</given-names></string-name>, <string-name><surname>Viana</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Schwarz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lisboa</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Dora</surname> <given-names>JMS</given-names></string-name>, <string-name><surname>Balsan</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Schirmer</surname> <given-names>FD</given-names></string-name>, <string-name><surname>Franz</surname> <given-names>JPM</given-names></string-name>, <string-name><surname>da-Silveira</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Breunig</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>V</given-names></string-name>, <string-name><surname>Sosnoski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mesquita</surname> <given-names>NF</given-names></string-name>, <string-name><surname>Volpato</surname> <given-names>FCZ</given-names></string-name>, <string-name><surname>Sganzerla</surname> <given-names>D</given-names></string-name>, <string-name><surname>Falavigna</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rosa</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Zavascki</surname> <given-names>AP</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial</article-title>. <source>Eur Respir J</source> doi:<pub-id pub-id-type="doi">10.1183/13993003.01471-2021</pub-id>.</mixed-citation></ref>
<ref id="c103"><label>103.</label><mixed-citation publication-type="journal"><string-name><surname>Devos</surname> <given-names>T</given-names></string-name>, <string-name><surname>Van Thillo</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Compernolle</surname> <given-names>V</given-names></string-name>, <string-name><surname>Najdovski</surname> <given-names>T</given-names></string-name>, <string-name><surname>Romano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dauby</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jadot</surname> <given-names>L</given-names></string-name>, <string-name><surname>Leys</surname> <given-names>M</given-names></string-name>, <string-name><surname>Maillart</surname> <given-names>E</given-names></string-name>, <string-name><surname>Loof</surname> <given-names>S</given-names></string-name>, <string-name><surname>Seyler</surname> <given-names>L</given-names></string-name>, <string-name><surname>Moonen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Moutschen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Van Regenmortel</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ari&#x00EB;n</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Barbezange</surname> <given-names>C</given-names></string-name>, <string-name><surname>Betrains</surname> <given-names>A</given-names></string-name>, <string-name><surname>Garigliany</surname> <given-names>M</given-names></string-name>, <string-name><surname>Engelen</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Gyselinck</surname> <given-names>I</given-names></string-name>, <string-name><surname>Maes</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schauwvlieghe</surname> <given-names>A</given-names></string-name>, <string-name><surname>Liesenborghs</surname> <given-names>L</given-names></string-name>, <string-name><surname>Belmans</surname> <given-names>A</given-names></string-name>, <string-name><surname>Verhamme</surname> <given-names>P</given-names></string-name>, <string-name><surname>Meyfroidt</surname> <given-names>G</given-names></string-name>. <year>2021</year>. <article-title>Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma</article-title>. <source>Eur Respir J</source> doi:<pub-id pub-id-type="doi">10.1183/13993003.01724-2021</pub-id>.</mixed-citation></ref>
<ref id="c104"><label>104.</label><mixed-citation publication-type="journal"><string-name><surname>Devos</surname> <given-names>T</given-names></string-name>, <string-name><surname>Geukens</surname> <given-names>T</given-names></string-name>, <string-name><surname>Schauwvlieghe</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ari&#x00EB;n</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Barbezange</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cleeren</surname> <given-names>M</given-names></string-name>, <string-name><surname>Compernolle</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dauby</surname> <given-names>N</given-names></string-name>, <string-name><surname>Desmecht</surname> <given-names>D</given-names></string-name>, <string-name><surname>Grimaldi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lambrecht</surname> <given-names>BN</given-names></string-name>, <string-name><surname>Luyten</surname> <given-names>A</given-names></string-name>, <string-name><surname>Maes</surname> <given-names>P</given-names></string-name>, <string-name><surname>Moutschen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Romano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Seyler</surname> <given-names>L</given-names></string-name>, <string-name><surname>Nevessignsky</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Vandenberghe</surname> <given-names>K</given-names></string-name>, <string-name><surname>van Griensven</surname> <given-names>J</given-names></string-name>, <string-name><surname>Verbeke</surname> <given-names>G</given-names></string-name>, <string-name><surname>Vlieghe</surname> <given-names>E</given-names></string-name>, <string-name><surname>Yombi</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Liesenborghs</surname> <given-names>L</given-names></string-name>, <string-name><surname>Verhamme</surname> <given-names>P</given-names></string-name>, <string-name><surname>Meyfroidt</surname> <given-names>G</given-names></string-name>. <year>2020</year>. <article-title>A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID- 19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial</article-title>. <source>Trials</source> <volume>21</volume>:<fpage>981</fpage>.</mixed-citation></ref>
<ref id="c105"><label>105.</label><mixed-citation publication-type="other"><string-name><surname>Menichetti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Popoli</surname> <given-names>P</given-names></string-name>, <string-name><surname>Puopolo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Spila Alegiani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tiseo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Bartoloni</surname> <given-names>A</given-names></string-name>, <string-name><surname>De Socio</surname> <given-names>G</given-names></string-name>, <string-name><surname>Luchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Blanc</surname> <given-names>P</given-names></string-name>, <string-name><surname>Puoti</surname> <given-names>M</given-names></string-name>, <string-name><surname>De Donno</surname> <given-names>G</given-names></string-name>, <string-name><surname>Toschi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Massari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Palmisano</surname> <given-names>L</given-names></string-name>, <string-name><surname>Marano</surname> <given-names>G</given-names></string-name>, <string-name><surname>Chiamenti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martinelli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Franchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pallotto</surname> <given-names>C</given-names></string-name>, <string-name><surname>Suardi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Luciani Pasqua</surname> <given-names>B</given-names></string-name>, <string-name><surname>Merli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fabiani</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bertolucci</surname> <given-names>L</given-names></string-name>, <string-name><surname>Borchi</surname> <given-names>B</given-names></string-name>, <string-name><surname>Modica</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moneta</surname> <given-names>S</given-names></string-name>, <string-name><surname>Marchetti</surname> <given-names>G</given-names></string-name>, <string-name><surname>d&#x2019;Arminio Monforte</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stoppini</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ferracchiato</surname> <given-names>N</given-names></string-name>, <string-name><surname>Piconi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fabbri</surname> <given-names>C</given-names></string-name>, <string-name><surname>Beccastrini</surname> <given-names>E</given-names></string-name>, <string-name><surname>Saccardi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Giacometti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Esperti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pierotti</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bernini</surname> <given-names>I</given-names></string-name>, <string-name><surname>Bianco</surname> <given-names>C</given-names></string-name>, <string-name><surname>Benedetti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lanzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bonfanti</surname> <given-names>P</given-names></string-name>, <string-name><surname>Massari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Saracino</surname> <given-names>A</given-names></string-name>, <string-name><surname>Castagna</surname> <given-names>A</given-names></string-name>, <string-name><surname>Trabace</surname> <given-names>I</given-names></string-name>, <string-name><surname>Lanza</surname> <given-names>M</given-names></string-name>, <string-name><surname>Focosi</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> 2021. <article-title>Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A Randomized Clinical Trial</article-title>. <source>JAMA Network Open</source>.</mixed-citation></ref>
<ref id="c106"><label>106.</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Li</surname> <given-names>W</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>J</given-names></string-name>, <string-name><surname>He</surname> <given-names>B</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>T</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Han</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>X</given-names></string-name>. <year>2020</year>. <article-title>Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis</article-title>. <source>Clin Transl Med</source> <volume>10</volume>:<fpage>e259</fpage>.</mixed-citation></ref>
<ref id="c107"><label>107.</label><mixed-citation publication-type="journal"><string-name><surname>Pappa</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bouchla</surname> <given-names>A</given-names></string-name>, <string-name><surname>Terpos</surname> <given-names>E</given-names></string-name>, <string-name><surname>Thomopoulos</surname> <given-names>TP</given-names></string-name>, <string-name><surname>Rosati</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stellas</surname> <given-names>D</given-names></string-name>, <string-name><surname>Antoniadou</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mentis</surname> <given-names>A</given-names></string-name>, <string-name><surname>Papageorgiou</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Politou</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kotanidou</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kalomenidis</surname> <given-names>I</given-names></string-name>, <string-name><surname>Poulakou</surname> <given-names>G</given-names></string-name>, <string-name><surname>Jahaj</surname> <given-names>E</given-names></string-name>, <string-name><surname>Korompoki</surname> <given-names>E</given-names></string-name>, <string-name><surname>Grigoropoulou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Bear</surname> <given-names>J</given-names></string-name>, <string-name><surname>Karaliota</surname> <given-names>S</given-names></string-name>, <string-name><surname>Burns</surname> <given-names>R</given-names></string-name>, <string-name><surname>Pagoni</surname> <given-names>M</given-names></string-name>, <string-name><surname>Trontzas</surname> <given-names>I</given-names></string-name>, <string-name><surname>Grouzi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Labropoulou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Stamoulis</surname> <given-names>K</given-names></string-name>, <string-name><surname>Bamias</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tsiodras</surname> <given-names>S</given-names></string-name>, <string-name><surname>Felber</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Pavlakis</surname> <given-names>GN</given-names></string-name>, <string-name><surname>Dimopoulos</surname> <given-names>MA</given-names></string-name>. <year>2021</year>. <article-title>A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis</article-title>. <source>Microorganisms</source> <volume>9</volume>:<fpage>806</fpage>.</mixed-citation></ref>
<ref id="c108"><label>108.</label><mixed-citation publication-type="journal"><string-name><surname>Salazar</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kuchipudi</surname> <given-names>SV</given-names></string-name>, <string-name><surname>Christensen</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Eagar</surname> <given-names>TN</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>P</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Long</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Olsen</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Castillo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Leveque</surname> <given-names>C</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Lavinder</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gollihar</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Cardona</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ippolito</surname> <given-names>GC</given-names></string-name>, <string-name><surname>Nissly</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Bird</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Greenawalt</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rossi</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Gontu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Srinivasan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Poojary</surname> <given-names>IB</given-names></string-name>, <string-name><surname>Cattadori</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Hudson</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Joselyn</surname> <given-names>N</given-names></string-name>, <string-name><surname>Prugar</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huie</surname> <given-names>K</given-names></string-name>, <string-name><surname>Herbert</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bernard</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Dye</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kapur</surname> <given-names>V</given-names></string-name>, <string-name><surname>Musser</surname> <given-names>JM</given-names></string-name>. <year>2020</year>. <article-title>Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization</article-title>. <source>J Clin Invest</source> <volume>130</volume>:<fpage>6728</fpage>&#x2013;<lpage>6738</lpage>.</mixed-citation></ref>
<ref id="c109"><label>109.</label><mixed-citation publication-type="journal"><string-name><surname>Tworek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jaro&#x0144;</surname> <given-names>K</given-names></string-name>, <string-name><surname>Uszy&#x0144;ska-Ka&#x0142;u&#x017C;a</surname> <given-names>B</given-names></string-name>, <string-name><surname>Rydzewski</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gil</surname> <given-names>R</given-names></string-name>, <string-name><surname>Depta&#x0142;a</surname> <given-names>A</given-names></string-name>, <string-name><surname>Franek</surname> <given-names>E</given-names></string-name>, <string-name><surname>W&#x00F3;jtowicz</surname> <given-names>R</given-names></string-name>, <string-name><surname>&#x017B;yci&#x0144;ska</surname> <given-names>K</given-names></string-name>, <string-name><surname>Walecka</surname> <given-names>I</given-names></string-name>, <string-name><surname>Cicha</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wierzba</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zaczy&#x0144;ski</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kr&#x00F3;l</surname> <given-names>ZJ</given-names></string-name>, <string-name><surname>Rydzewska</surname> <given-names>G</given-names></string-name>. <year>2021</year>. <article-title>Convalescent plasma treatment is associated with lower mortality and better outcomes in high risk COVID-19 patients - propensity score matched case-control study</article-title>. <source>Int J Infect Dis</source> <volume>105</volume>:<fpage>209</fpage>&#x2013;<lpage>215</lpage>.</mixed-citation></ref>
<ref id="c110"><label>110.</label><mixed-citation publication-type="journal"><string-name><surname>Chauhan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Pattee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ford</surname> <given-names>J</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lesteberg</surname> <given-names>K</given-names></string-name>, <string-name><surname>Richards</surname> <given-names>E</given-names></string-name>, <string-name><surname>Loi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Annen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Berg</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zirbes</surname> <given-names>M</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Monkowski</surname> <given-names>D</given-names></string-name>, <string-name><surname>Boxer</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Beckham</surname> <given-names>JD</given-names></string-name>. <year>2021</year>. <article-title>A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients</article-title>. <source>medrXiv [Preprint]</source> doi:<pub-id pub-id-type="doi">10.1101/2021.06.14.21258910</pub-id> &#x0025;J medRxiv:2021.06.14.21258910.</mixed-citation></ref>
</ref-list>
</back>
</article>